

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number
WO 02/12224 A2(51) International Patent Classification⁷: C07D 333/20, 307/52, 295/096, 295/135, 233/60, 233/58, C07C 335/32, C07D 233/84, 277/36, 233/88, 207/325, 295/112, 207/335, C07C 323/32, 225/16, A61K 31/381, 31/341, 31/40, 31/4453, 31/4164, A61P 25/00, 9/00

(21) International Application Number: PCT/US01/24654

(22) International Filing Date: 6 August 2001 (06.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/223,768 8 August 2000 (08.08.2000) US
09/922,622 6 August 2001 (06.08.2001) US

(71) Applicant: ORTHO MCNEIL PHARMACEUTICAL, INC. [US/US]; U.S. Route 202, P.O. Box 300, Raritan, NJ 08869-0602 (US).

(72) Inventors: BOGENSTAETTER, Michael; 239 24th Street, Del Mar, CA 92014 (US). CHAI, Wenyi; 9519 Compass Point Drive South, San Diego, CA 92126 (US). KWOK, Annette, K.; 10770 Aderman Avenue, #92, San Diego, CA 92126 (US).

(74) Agents: JOHNSON, Philip, S. et al.; One Johnson & Johnson Plaza, New Brunswick, NJ 08903 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/12224 A2

(54) Title: BICYCLIC COMPOUNDS

(57) Abstract: Substituted N-substituted alkoxyphenyl compounds, compositions containing them, and methods of making and using them.

BICYCLIC COMPOUNDSField of the Invention

The present invention relates to bicyclic derivatives, their synthesis and their
10 use, for example, for the treatment of disorders and conditions mediated by the
histamine receptor.

Background of the Invention

15 Histamine [2-(imidazol-4-yl)ethylamine] is a transmitter substance. Histamine exerts a physiological effect via multiple distinct G-protein coupled receptors. It plays a role in immediate hypersensitivity reactions and is released from mast cells following antigen IgE antibody interaction. The actions of released histamine on the vasculature and smooth muscle system account for the symptoms of the allergic
20 response. These actions occur at the H₁ receptor (Ash, A.S.F. and Schild, H.O., *Br. J. Pharmacol.*, 1966, 27, 427) and are blocked by the classical antihistamines (e.g. diphenhydramine). Histamine is also an important regulator of gastric acid secretion through its action on parietal cells. These effects of histamine are mediated via the H₂ receptor (Black, J.W., Duncan, W.A.M., Durant, C.J., Ganellin, C.R. and Parsons,
25 E. M., *Nature*, 1972, 236, 385) and are blocked by H₂ receptor antagonists (e.g. cimetidine). The third histamine receptor —H₃— was first described as a presynaptic autoreceptor in the central nervous system (CNS) (Arrang, J.-M., Garbarg, M., and Schwartz, J.-C., *Nature* 1983, 302, 832) controlling the synthesis and release of histamine. Recent evidence has emerged showing that the H₃
30 receptors are also located presynaptically as heteroreceptors on serotonergic, noradrenergic, dopaminergic, cholinergic, and GABAergic (gamma-aminobutyric acid containing) neurons. These H₃ receptors have also recently been identified in peripheral tissues such as vascular smooth muscle. Consequently there are many

5 potential therapeutic applications for histamine H₃ agonists, antagonists, and inverse agonists. (See: "The Histamine H₃ Receptor-A Target for New Drugs", Leurs, R., and Timmerman, H., (Editors), Elsevier, 1998; Morisset et al., *Nature*, 2000, **408**, 860-864.) A fourth histamine receptor —H₄— was recently described by Oda et al., (J. Biol. Chem., 2000, **275**, 36781-36786).

10

The potential use of histamine H₃ agonists in sleep/wake and arousal/vigilance disorders is suggested based on animal studies (Lin et al, *Br. Res.*, 1990, **523**, 325; Monti et al *Eur. J. Pharmacol.*, 1991, **205**, 283). Their use in the treatment of migraine has also been suggested (McLeod et al *Abstr. Society*

15 *Neuroscience*, 1996, **22**, 2010) based on their ability to inhibit neurogenic inflammation. Other applications could be a protective role in myocardial ischemia and hypertension where blockade of norepinephrine release is beneficial (Imamura et al *J. Pharmacol. Expt. Ther.*, 1994, **271**, 1259). It has been suggested that histamine H₃ agonists may be beneficial in asthma due to their ability to reduce non-20 adrenergic non-cholinergic (NANC) neurotransmission in airways and to reduce microvascular leakage (Ichinose et al *Eur. J. Pharmacol.*, 1989, **174**, 49).

Several indications for histamine H₃ antagonists and inverse agonists have similarly been proposed based on animal pharmacology experiments with known 25 histamine H₃ antagonists (e.g. thioperamide). These include dementia, Alzheimer's disease (Panula et al *Abstr. Society Neuroscience*, 1995, **21**, 1977), epilepsy (Yokoyama et al *Eur. J. Pharmacol.*, 1993, **234**, 129) narcolepsy, eating disorders (Machidori et al *Brain Research* 1992, **590**, 180), motion sickness, vertigo, attention deficit hyperactivity disorders (ADHD), learning and memory (Barnes et al *Abstr. 30 Society Neuroscience*, 1993, **19**, 1813), schizophrenia (Schlicker et al *Naunyn-Schmiedeberg's Arch. Pharmacol.*, 1996, **353**, 290-294); (also see; Stark et al *Drugs Future*, 1996, **21**; 507 and Leurs et al *Progress in Drug Research*, 1995, **45**, 107 and references cited therein). Histamine H₃ antagonists, alone or in

5 combination with a histamine H₁ antagonist, are reported to be useful for the treatment of upper airway allergic response (U.S. Patent Nos. 5,217,986; 5,352,707 and 5,869,479). Recently, a histamine H₃ antagonist (GT-2331) was identified and is being developed by Gliatech Inc. (Gliatech Inc. Press Release Nov. 5, 1998; *Bioworld Today*, March 2, 1999) for the treatment of CNS disorders.

10

As noted, the prior art related to histamine H₃ ligands has been comprehensively reviewed ("The Histamine H₃ Receptor-A Target for New Drugs", Leurs, R., and Timmerman, H., (Editors), Elsevier, 1998). Within this reference the medicinal chemistry of histamine H₃ agonists and antagonists was reviewed (see 15 Krause et al and Phillips et al respectively). The importance of an imidazole moiety containing only a single substitution in the 4 position was noted together with the deleterious effects of additional substitution on activity. Particularly methylation of the imidazole ring at any of the remaining unsubstituted positions was reported to strongly decrease activity. Additional publications support the hypothesis that an 20 imidazole function is essential for high affinity histamine H₃ receptor ligands (See, Ali et al *J. Med. Chem.*, 1999, 42, 903 and Stark et al, *Drugs Future*, 1996, 21, 507 and references cited therein). However many imidazole containing compounds are substrates for histamine methyl transferase, the major histamine metabolizing 25 enzyme in humans, which leads to shortened half lives and lower bioavailability (See, Rouleau et al *J. Pharmacol. Exp. Ther.* 1997, 281, 1085). In addition, imidazole containing drugs, via their interaction with the cytochrome P450 monooxygenase system, can result in unfavorable biotransformations due to 30 enzyme induction or enzyme inhibition. (Kapetanovic et al *Drug Metab. Dispos.* 1984, 12, 560; Sheets et al *Drug Metab. Dispos.* 1984, 12, 603; Back, et al *Br. J. Pharmacol.* 1985, 85, 121; Lavrijsen et al *Biochem. Pharmacol.* 1986, 35, 1867; *Drug Saf.*, 1998, 18, 83). The poor blood brain barrier penetration of earlier histamine H₃ receptor ligands may also be associated with the imidazole fragment (Ganellin et al *Arch. Pharm. (Weinheim, Ger.)* 1998, 331, 395).

5


More recently, several publications have described histamine H₃ ligands that do not contain an imidazole moiety. For example; Ganellin et al *Arch. Pharm. (Weinheim, Ger.)* 1998, 331, 395; Walczynski et al *Arch. Pharm. (Weinheim, Ger.)* 1999, 332, 389; Walczynski et al *Farmaco* 1999, 684; Linney et al *J. Med. Chem.* 10 2000, 2362; Tozer and Kalindjian *Exp. Opin. Ther. Patents* 2000, 10, 1045-1055; U.S. Patent 5,352,707; PCT Application WO99/42458, Aug 26, 1999; and European Patent Application 0978512, Feb 9, 2000.

The compounds of the present invention do not contain the imidazole moiety, 15 and its inherent liabilities, and maintain potency at the human H₃ receptor. Thus in the present invention receptor binding was determined using the human histamine H₃ receptor (See Lovenberg et al *Mol. Pharmacol.* 1999, 1107). Screening using the human receptor is particularly important for the identification of new therapies for the treatment of human disease. Conventional binding assays for example are 20 determined using rat synaptosomes (Garbarg et al *J. Pharmacol. Exp. Ther.* 1992, 263, 304), rat cortical membranes (West et al *Mol. Pharmacol.* 1990, 610), and guinea pig brain (Korte et al *Biochem. Biophys. Res. Commun.* 1990, 978). Only limited studies have been performed previously using human tissue but these allude to significant differences in the pharmacology of rodent and primate receptors (West 25 et al *Eur. J. Pharmacol.* 1999, 233).

We now describe a series of bicyclic derivatives with the ability to modulate the activity of the histamine receptor, specifically the H₃ receptor, without the inherent problems associated with the presence of an imidazolyl moiety.

5 Summary of the Invention

The present invention is directed to a compound of formula (I):



10

wherein each of W_1 and W_2 is H;

X_1 is selected from G_a , $R_a G_a$, $L_a G_a$, and $R_a L_a G_a$;

15

X_2 is selected from G_b , $R_b G_b$, $L_b G_b$, and $R_b L_b G_b$;

each of G_a and G_b is independently $NR_{3a}R_{4a}$ or $NR_{3b}R_{4b}$, respectively, or pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, isoindolinyl, morpholinyl, piperazinyl, imidazolyl, thiazolinyl, 5,6-dihydro-3-imidazo[2,1-B]thiazolyl, or thiazolyl;

20 wherein each of R_{3a} , R_{4a} , R_{3b} and R_{4b} is independently selected from H, C_{1-8} alkyl, C_{3-7} cycloalkyl, and $(C_{3-7}$ cycloalkyl) C_{1-6} alkyl;

G_b can be further selected from nitro, halo, OH, CHO, pyrrolyl, or $-C(=NOH)H$;

25

each of R_a and R_b is independently O, S, NH or C=O;

each of L_a and L_b is independently C_{1-3} alkylene;

5 Y is a covalent bond where one of Z₁ and Z₂ is N, O, or S; Y can also be SO₂, C=O, CH₂, CH₂CH₂, OCH₂, CH₂O, or NR_c, wherein R_c is H, C₁₋₈ alkyl, C₃₋₇ cycloalkyl, (C₃₋₇ cycloalkyl)C₁₋₆ alkyl, C₂₋₅ heterocyclyl, (C₂₋₇ heterocyclyl)C₁₋₆ alkyl, phenyl, (phenyl)C₁₋₆ alkyl, or [di (C₁₋₆ alkyl)amino]C₁₋₆ alkyl;

10 each of Z₁ and Z₂ is independently N, O, S, or -CH=CH- to form a phenyl ring; or a pharmaceutically acceptable salt, amide or ester thereof.

The invention also features a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier; and methods of preparing or formulating such compositions. A composition of the invention may further include more than one compound of the invention, or a combination therapy (combination formulation or administering a combination of differently formulated active agents).

20 The invention also provides methods of treating certain conditions and diseases, each of which methods includes administering a therapeutically effective (or jointly effective) amount of a compound or composition of the invention to a subject in need of such treatment. The disclosed compounds are useful in methods for treating or preventing neurologic disorders including sleep/wake and arousal/vigilance disorders (e.g. insomnia and jet lag), attention deficit hyperactivity disorders (ADHD), learning and memory disorders, cognitive dysfunction, migraine, neurogenic inflammation, dementia, mild cognitive impairment (pre-dementia), Alzheimer's disease, epilepsy, narcolepsy, eating disorders, obesity, motion sickness, vertigo, schizophrenia, substance abuse, bipolar disorders, manic disorders and depression, as well as other histamine H₃ receptor mediated disorders such as upper airway allergic response, asthma, itch, nasal congestion and allergic rhinitis in a subject in need thereof. For example, the invention features methods for

5 preventing, inhibiting the progression of, or treating upper airway allergic response, asthma, itch, nasal congestion and allergic rhinitis.

In yet another embodiment, the disclosed compounds may be used in a combination therapy method including administering a jointly effective dose of an H₃ antagonist and administering a jointly effective dose of a histamine H₁ antagonist,

10 such as loratadine (CLARITINTM), desloratadine (CLARINEXTM), fexofenadine (ALLEGRATM) and cetirizine (ZYRTECTM), for the treatment of allergic rhinitis, nasal congestion, and allergic congestion.

In yet another embodiment, the disclosed compounds may be used in a combination therapy method, including administering a jointly effective dose of an H₃

15 antagonist and administering a jointly effective dose of a neurotransmitter re-uptake blocker, such as a selective serotonin re-uptake inhibitor (SSRI) or a non-selective serotonin, dopamine or norepinephrine re-uptake inhibitor, including fluoxetine (PROZACTM), sertraline (ZOLOFTTM), paroxetine (PAXILTM) and amitryptyline, for the treatment of depression, mood disorders or schizophrenia.

20

Additional features and advantages of the invention will become apparent from the detailed description and examples below, and the appended claims.

5

Detailed Description of the Invention

The present invention provides bicyclic compounds useful for the treatment of disorders and conditions modulated by a histamine receptor.

10 A. Terms

Certain terms are defined below and by their usage throughout this disclosure.

As used herein, "halogen" shall mean chlorine, bromine, fluorine and iodine, or
15 monovalent radicals thereof.

As used herein, the term "alkyl", whether used alone or as part of a
substituent group, shall include straight and branched carbon chains. For example,
alkyl radicals include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-
20 butyl, pentyl and the like. Unless otherwise noted, "lower" when used with alkyl
means a carbon chain composition of 1-4 carbon atoms. "Alkylene" refers to a
bivalent hydrocarbyl group, such as methylene (CH_2), ethylene ($-\text{CH}_2-\text{CH}_2-$) or
propylene ($-\text{CH}_2\text{CH}_2\text{CH}_2-$).

25 As used herein, unless otherwise noted, "alkoxy" shall denote an oxygen ether
radical of the above described straight or branched chain alkyl groups. For example,
methoxy, ethoxy, n-propoxy, sec-butoxy, t-butoxy, n-hexyloxy and the like.

As used herein, unless otherwise noted, "cycloalkyl" shall denote a three- to
30 eight -membered, saturated monocyclic carbocyclic ring structure. Suitable examples
include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

5 As used herein, unless otherwise noted, "cycloalkenyl" shall denote a three- to eight-membered, partially unsaturated, monocyclic, carbocyclic ring structure, wherein the ring structure contains at least one double bond. Suitable examples include cyclohexenyl, cyclopentenyl, cycloheptenyl, cyclooctenyl, cyclohex-1,3-dienyl and the like.

10 As used herein, unless otherwise noted, "aryl" shall refer to carbocyclic aromatic groups such as phenyl, naphthyl, and the like. Divalent radicals include phenylene (-C₆H₄-) which is preferably phen-1,4-diyl, but may also be phen-1,3-diyl.

15 As used herein, unless otherwise noted, "aralkyl" shall mean any alkyl group substituted with an aryl group such as phenyl, naphthyl and the like. Examples of aralkyls include benzyl, phenethyl, and phenylpropyl.


20 As used herein, unless otherwise noted, the terms "heterocycle", "heterocyclyl" and "heterocyclo" shall denote any five-, six-, or seven- membered monocyclic, nine or ten membered bicyclic or thirteen or fourteen membered tricyclic ring structure containing at least one heteroatom moiety selected from the group consisting of N, O, 25 SO, SO₂, (C=O), and S, and preferably N, O, or S, optionally containing one to four additional heteroatoms in each ring. In some embodiments, the heterocyclyl contains between 1 and 3 or between 1 and 2 additional heteroatoms. Unless otherwise specified, a heterocyclyl may be saturated, partially unsaturated, aromatic or partially aromatic. The heterocyclyl group may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.

30 Exemplary monocyclic heterocyclic groups can include pyrrolidinyl, pyrrolyl, indolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thiazaolyl, thiadiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, furyl, tetrahydrofuryl, thienyl, oxadiazolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxazepinyl,

5 azepinyl, hexahydroazepinyl, 4-piperidinyl, pyridyl, N-oxo-pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, tetrahydropyranly, tetrahydrothiopyranly, tetrahydrothiopyranly sulfone, morpholinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl sulfone, 1,3-dixolane and tetrahydro-1,1-dioxothienyl, dioxanyl, isothiazolidinyl, thietanyl, thiiranyl, triazinyl, triazolyl, tetrazolyl, azetidinyl
 10 and the like.

Exemplary bicyclic heterocyclic groups include benzthiazolyl, benzoxazolyl, benzoxazinyl, benzothienyl, quinuclidinyl, quinolinyl, quinolinyl-N-oxide, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranly, indolizinyl,

15 benzofuryl, chromonyl, coumarinyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopridyl, furopyridinyl (such as furo[2,3-c]pyridinyl, furo[3,1-b]pyridinyl), or furo[2,3-b]pyridinyl, dihydroisoindolyl, dihydroquinazolinyl (such as 3,4-dihydro-4-oxo-quinazolinyl), tetrahydroquinolinyl (such as 1,2,3,4-tetrahydroquinolinyl), tetrahydroisoquinolinyl (such as 1,2,3,4-tetrahydroisoquinolinyl), benzisothiazolyl,
 20 benzisoxazolyl, benzodiazinyl, benzofurazanyl, benzothiopyranly, benzotriazolyl, benzpyrazolyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranly, dihydrobenzothiopyranly sulfone, dihydrobenzopyranly, indolinyl, isoindolyl, tetrahydroindoazolyl (such as 4,5,6,7-tetrahydroindoazolyl), isochromanyl, isoindolinyl, naphthyridinyl, phthalazinyl, piperonyl, purinyl, pyridopyridyl,
 25 quinazolinyl, tetrahydroquinolinyl, thienofuryl, thienopyridyl, thienothienyl,




, and the like.

Exemplary tricyclic heterocyclic groups include acridinyl, phenoxazinyl, phenazinyl, phenothiazinyl, carbozolyl, perimidinyl, phenanthrolinyl, carbolinyl,
 30 naphthothienyl, thianthrenyl, and the like.

5

Preferred heterocyclyl groups include morpholiny, piperidiny, piperaziny, pyrrolidiny, pyrimidiny, pyridyl, pyrrolyl, imidazolyl, oxazolyl, isoxazolyl, acridiny, azepiny, hexahydroazepiny, azetidiny, indolyl, isoindolyl, thiazolyl, thiadiazolyl, quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroquinolinyl, 1,3,4-trihydroisoquinolinyl,

10 4,5,6,7-tetrahydroindadolyl, benzoxaziny, benzoaxzolyl, benzthiazolyl, benzimidazolyl,



tetrazolyl, oxadiazolyl,

As used herein, unless otherwise noted, the term "heterocyclyl-alkyl" or "heterocyclyl-alkylene" shall denote any alkyl group substituted with a heterocyclyl group, wherein the heterocyclyl-alkyl group is bound through the alkyl portion to the central part of the molecule. Suitable examples of heterocyclyl-alkyl groups include, but are not limited to piperidinylmethyl, pyrrolidinylmethyl, piperidinylethyl, piperazinylmethyl, pyrrolylbutyl, piperidinylisobutyl, pyridylmethyl, pyrimidylethyl, and the like.

20


When a particular group is "substituted" (e.g., alkyl, alkylene, cycloalkyl, aryl, heterocyclyl, heteroaryl), that group may have one or more substituents, preferably from one to five substituents, more preferably from one to three substituents, most preferably from one to two substituents, independently selected from the list of 25 substituents.

It is intended that the definition of any substituent or variable at a particular location in a molecule be independent of its definitions elsewhere in that molecule. It is understood that substituents and substitution patterns on the compounds of this 30 invention can be selected by one of ordinary skill in the art to provide compounds

5 that are chemically stable and that can be readily synthesized by techniques known in the art as well as those methods set forth herein.

Under standard nomenclature used throughout this disclosure, the terminal portion of the designated side chain is described first, followed by the adjacent

10 functionality toward the point of attachment. Thus, for example, a "phenyl(alkyl)amido(alkyl)" substituent refers to a group of the formula



15 The term "subject" as used herein, refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.

20 The term "therapeutically effective amount" as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes prevention, inhibition of onset, or alleviation of the symptoms of the disease or disorder being treated.

25 As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.

5 Abbreviations used in the specification, particularly in the Schemes and Examples, are as follows:

DBAD	=	di- <i>tert</i> -butyl azodicarboxylate
DCE	=	1,2-dichloroethane
DCM	=	dichloromethane
DEAD	=	diethyl azodicarboxylate
DMA	=	<i>N,N</i> -dimethylacetamide
DMAP	=	4- <i>N,N</i> -dimethylamino-pyridine
DME	=	1,2-dimethoxyethane
DMF	=	dimethylformamide
DMSO	=	dimethylsulfoxide
RT	=	room temperature
TEA	=	triethylamine
TFA	=	trifluoroacetic acid
THF	=	tetrahydrofuran

10 The next section describes the compounds provided by the invention in more detail.

B. Compounds

15 The invention features compounds of formula (I) as described, for example, in the above Summary section and in the claims. Preferred compounds include those wherein:

5 (a) each of G_a and G_b is independently $NR_{3a}R_{4a}$ or $NR_{3b}R_{4b}$, respectively, or
pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, isoindolinyl,
morpholinyl, piperazinyl, imidazolyl, thiazolinyl, 5,6-dihydro-3-imidazo[2,1-
B]thiazolyl, or thiazolyl; wherein each of R_{3a} , R_{4a} , R_{3b} and R_{4b} is
independently selected from H, C₁₋₈ alkyl, C₃₋₇ cycloalkyl, and (C₃₋₇
10 cycloalkyl)C₁₋₆ alkyl;

(b) wherein X_1 is L_aG_a ;

(c) X_2 is L_bG_b ;

(d) X_1 is L_aG_a and X_2 is L_bG_b ;

(e) X_1 and X_2 are independently selected from pyrrolidinylmethyl,
15 piperidylmethyl, di(C₁₋₂ alkyl)amino (C₂₋₅ alkyl), and di(C₁₋₂ alkyl)amino(C₂₋₅ alkoxy);

(f) X_1 is selected from G_a , R_aG_a , or $R_aL_aG_a$;

(g) X_2 is selected from G_b , R_bG_b , or $R_bL_bG_b$;

(h) X_1 and X_2 are the same;

20 (i) each of G_a and G_b is independently NR_3R_4 , pyrrolidinyl, imidazolidinyl,
pyrazolidinyl, piperidyl, isoindolinyl, morpholinyl, thiazolyl, thiazolinyl, 5,6-
dihydro-3-imidazo[2,1-B]thiazolyl, or piperazinyl; where R_3 and R_4 are
each independently selected from H and C₁₋₄ alkyl;

(j) Y is O, S, SO₂, C=O, CH₂, OCH₂, CH₂O, or NR_c, wherein R_c is H, C₁₋₈
25 alkyl, C₃₋₇ cycloalkyl, (C₃₋₇ cycloalkyl)C₁₋₆ alkyl, C₂₋₅ heterocyclyl, (C₂₋₇
heterocyclyl)C₁₋₆ alkyl, phenyl, (phenyl)C₁₋₄ alkyl, or [di (C₁₋₄
alkyl)amino]C₁₋₆ alkyl; or

(k) combinations of the above.

30 The invention provides compounds such as: 1-[(4-(4-Pyrrolidin-1-ylmethyl)-
phenyl)-thiophen]-2-ylmethyl]-pyrrolidine; 1-[(4-(4-Pyrrolidin-1-ylmethyl-phenyl)-
furan)-2-ylmethyl]-pyrrolidine; 1-((4-(4-Pyrrolidin-1-ylmethyl-thiophen)-2-ylthiophen)-
2-ylmethyl)-pyrrolidine; 1-[(2-(4-Pyrrolidin-1-ylmethyl-phenyl)-thiophen)-3-ylmethyl]-

5 pyrrolidine; 1-[(3-(4-Pyrrolidin-1-ylmethyl-phenyl)-thiophen)-2-ylmethyl]-pyrrolidine; and 1-((4-(4-Pyrrolidin-1-ylmethyl-pyridin)-2-ylpyridin)-2-ylmethyl)-pyrrolidine .

Additional compounds of the invention include: 1-[4-(3,5-Dichloro-phenoxy)-benzyl]-pyrrolidine; 1-[4-(4-Piperidine-phenylsulfanyl)-3-nitro-benzyl]-piperidine; 4'-Pyrrolidin-1-ylmethyl-biphenyl-4-carbaldehyde; 4'-Pyrrolidin-1-ylmethyl-biphenyl-4-10 carbaldehyde oxime; 3-Pyrrolidin-1-ylmethyl-1-(4-pyrrolidin-1-ylmethyl-benzyl)-1H-pyrrole; and 2-Pyrrolidin-1-ylmethyl-1-(4-pyrrolidin-1-ylmethyl-benzyl)-1H-pyrrole.

Further examples of compounds include: 1-[4-(4-Pyrrolidin-1-ylmethyl-phenoxy)-benzyl]-pyrrolidine; 1-[4-(4-Piperidin-1-ylmethyl-phenoxy)-benzyl]-piperidine; 1-[4-(4-Pyrrolidin-1-ylmethyl-benzenesulfonyl)-benzyl]-pyrrolidine; 1-[4-(4-Pyrrolidin-1-ylmethyl-benzyl)-benzyl]-pyrrolidine; 1-[4-(4-Imidazo-1-ylmethyl-phenoxy)-benzyl]-imidazole; 1-[4-(4-Imidazo-1-ylmethyl-benzyl)-benzyl]-imidazole; [4-(N, N'-dimethyl-isothiourea)-methyl-phenoxy]-benzyl]-N, N'-dimethyl-isothiourea; [4-(N-methyl-isothiourea)-methyl-phenoxy]-benzyl]-N-methyl-isothiourea; 2-[4-(4-(2-Imidazolidin)-2-ylthiomethyl-phenoxy)-benzyl-thio]-2-imidazolidine; 2-[4-(4-(2-Thiazolin)-2-ylthiomethyl-phenoxy)-benzyl-thio]-2-thiazoline; 2-[4-(4-(1-Methylimidazo)-2-ylthiomethyl-phenoxy)-benzyl-thio]-1-methyl-imidazole; 2-[4-(4-(2-Imidazolidin)-2-ylaminomethyl-phenoxy)-benzyl-amino]-2-imidazolidine; and 1-(2-[2-(1-phenethyl-pyrrolidine)-ethyl]-phenyl)-ethyl]-pyrrolidine.

Additional compounds include: (A) 1-[4-(4-Bromo-benzyloxy)-benzyl]-pyrrolidine; 1-[4-(4-Pyrrolidin-1-ylmethyl-phenoxy-methyl)-benzyl]-1H-pyrrole; and 1-(4-Pyrrolidin-1-ylmethyl-benzyl)-1H-pyrrole; (B) Benzyl-(4-pyrrolidin-1-ylmethyl-phenyl)-amine; Benzyl-bis-(4-pyrrolidin-1-ylmethyl-phenyl)-amine; (3-Piperidin-1-yl-propyl)-bis-(4-pyrrolidin-1-ylmethyl-phenyl)-amine; and (2-(N,N-dimethylamine)ethyl)-bis-(4-pyrrolidin-1-ylmethyl-phenyl)-amine; and 3-[4-(4-(5,6-Dihydro-3-imidazo[2,1-B]thiazol)-3-ylphenoxy)-phenyl]- (5,6-dihydro-3-imidazo[2,1-B]thiazole); (D) Bis-[4-(3-dimethylamino-propylsulfanyl)-phenyl]-methanone dihydrochloride; Bis-[4-(3-dimethylamino-propoxy)-phenyl]-methanone;

5 [4-(3-Dimethylamino-propoxy)-phenyl]-(4-hydroxy-phenyl)-methanone; and (E) Bis-[4-(2-dimethylamino-ethoxy)-phenyl]-methanone.

The invention also provides compounds that are useful as synthetic intermediates of the compounds of the invention. Such compounds, which 10 themselves may or may not have pharmaceutical activity, include those provided in the schemes and synthetic examples.

The invention also contemplates compounds of the invention that have been isotopically modified to be detectable by positron emission tomography (PET) or 15 single-photon emission computed tomography (SPECT), and methods of studying disorders mediated by the histamine H₃ receptor, comprising using an ¹⁸F-labeled compound of claim 1 as a positron emission tomography (PET) molecular probe.

During any of the processes for preparation of the compounds of the present 20 invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. In addition, compounds of the invention may be modified by using protecting groups; such compounds, precursors, or prodrugs are also within the scope of the invention. This may be achieved by means of conventional protecting groups, such as those described in "Protective Groups in 25 Organic Chemistry", ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, "Protective Groups in Organic Synthesis", 3rd ed., John Wiley & Sons, 1999. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

30 HYDROXYL PROTECTING GROUPS

Protection for the hydroxyl group includes methyl ethers, substituted methyl ethers, substituted ethyl ethers, substitute benzyl ethers, and silyl ethers.

5

Substituted Methyl Ethers

Examples of substituted methyl ethers include methyoxyethyl, methylthiomethyl, *t*-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl, benzyloxymethyl, *p*-methoxybenzyloxymethyl, (4-methoxyphenoxy)methyl, 10 guaiacolmethyl, *t*-butoxymethyl, 4-pentenyoxyethyl, siloxymethyl, 2-methoxyethoxymethyl, 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl, tetrahydropyranyl, 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl, 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl S,S-dioxido, 1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl, 1,4-dioxan-2-yl, tetrahydrofuranyl, 15 tetrahydrothiofuranyl and 2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl.

Substituted Ethyl Ethers

20 Examples of substituted ethyl ethers include 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylselenyl)ethyl, *t*-butyl, allyl, *p*-chlorophenyl, *p*-methoxyphenyl, 2,4-dinitrophenyl, and benzyl.

25

Substituted Benzyl Ethers

Examples of substituted benzyl ethers include *p*-methoxybenzyl, 3,4-dimethoxybenzyl, *o*-nitrobenzyl, *p*-nitrobenzyl, *p*-halobenzyl, 2,6-dichlorobenzyl, *p*-cyanobenzyl, *p*-phenylbenzyl, 2- and 4-picoly, 3-methyl-2-picoly N-oxido, 30 diphenylmethyl, *p*, *p*'-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, α -naphthylidiphenylmethyl, *p*-methoxyphenylidiphenylmethyl, di(*p*-methoxyphenyl)phenylmethyl, tri(*p*-methoxyphenyl)methyl, 4-(4'-bromophenacyloxy)phenylidiphenylmethyl, 4,4',4''-tris(4,5-

5 dichlorophthalimidophenyl)methyl, 4,4',4''-tris(levulinoyloxyphenyl)methyl, 4,4',4''-tris(benzoyloxyphenyl)methyl, 3-(Imidazol-1-ylmethyl)bis(4',4''-dimethoxyphenyl)methyl, 1,1-bis(4-methoxyphenyl)-1'-pyrenylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl, 1,3-benzodithiolan-2-yl, and benzisothiazolyl S,S-dioxido.

10

Silyl Ethers

Examples of silyl ethers include trimethylsilyl, triethylsilyl, triisopropylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, dimethylhexylsilyl, *t*-butyldimethylsilyl, *t*-butyldiphenylsilyl, tribenzylsilyl, tri-*p*-xylylsilyl, triphenylsilyl, diphenylmethylsilyl, and

15 *t*-butylmethoxyphenylsilyl.

Esters

In addition to ethers, a hydroxyl group may be protected as an ester.

Examples of esters include formate, benzoylformate, acetate, chloroacetate,

20 dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, *p*-chlorophenoxyacetate, *p*-*P*-phenylacetate, 3-phenylpropionate, 4-oxopentanoate(levulinate), 4,4-(ethylenedithio)pentanoate, pivaloate, adamantoate, crotonate, 4-methoxycrotonate, benzoate, *p*-phenylbenzoate, 2,4,6-trimethylbenzoate(mesitoate)

25

Carbonates

Examples of carbonates include methyl, 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, 2-(triphenylphosphonio)ethyl, isobutyl, vinyl, allyl, *p*-nitrophenyl, benzyl, *p*-

30 methoxybenzyl, 3,4-dimethoxybenzyl, *o*-nitrobenzyl, *p*-nitrobenzyl, S-benzyl thiocarbonate, 4-ethoxy-1-naphthyl, and methyl dithiocarbonate.

5 Assisted Cleavage

Examples of assisted cleavage include 2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylpentanoate, o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl carbonate, 4-(methylthiomethoxy)butyrate, and 2-(methylthiomethoxymethyl)benzoate.

10

Miscellaneous Esters

Examples of miscellaneous esters include 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, 15 monosuccinate, (E)-2-methyl-2-butenoate(tiglate), o-(methoxycarbonyl)benzoate, p-P-benzoate, α -naphthoate, nitrate, alkyl N,N,N',N'-tetramethylphosphorodiamidate, N-phenylcarbamate, borate, dimethylphosphinothioyl, and 2,4-dinitrophenylsulfenate

20 Sulfonates

Examples of sulfonates include sulfate, methanesulfonate(mesylate), benzylsulfonate, and tosylate.

PROTECTION FOR 1,2- AND 1,3-DIOLS

25

Cyclic Acetals and Ketals

Examples of cyclic acetals and ketals include methylene, ethylidene, 1-t-butylethylidene, 1-phenylethylidene, (4-methoxyphenyl)ethylidene, 2,2,2-trichloroethylidene, acetonide (isopropylidene), cyclopentylidene, cyclohexylidene, 30 cycloheptylidene, benzylidene, p-methoxybenzylidene, 2,4-dimethoxybenzylidene, 3,4-dimethoxybenzylidene, and 2-nitrobenzylidene.

Cyclic Ortho Esters

5 Examples of cyclic ortho esters include methoxymethylene, ethoxymethylene, dimethoxymethylene, 1-methoxyethylidene, 1-ethoxyethylidene, 1,2-dimethoxyethylidene, α -methoxybenzylidene, 1-(N,N-dimethylamino)ethylidene derivative, α -(N,N-dimethylamino)benzylidene derivative, and 2-oxacyclopentylidene.

10

Silyl Derivatives

Examples of silyl derivatives include di-*t*-butylsilylene group, and 1,3-(1,1,3,3-tetraisopropylsiloxyanlylidene) derivative.

15

AMINO PROTECTING GROUPS

Protection for the amino group includes carbamates, amides, and special –NH protective groups.

20

Examples of carbamates include methyl and ethyl carbamates, substituted ethyl carbamates, assisted cleavage carbamates, photolytic cleavage carbamates, urea-type derivatives, and miscellaneous carbamates.

Carbamates

25

Examples of methyl and ethyl carbamates include methyl and ethyl, 9-fluorenylmethyl, 9-(2-sulfo)fluorenylmethyl, 9-(2,7-dibromo)fluorenylmethyl, 2,7-di-*t*-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)methyl, and 4-methoxyphenacyl.

30

Substituted Ethyl

Examples of substituted ethyl carbamates include 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-phenylethyl, 1-(1-adamantyl)-1-methylethyl, 1,1-dimethyl-2-haloethyl, 1,1-dimethyl-2,2-dibromoethyl, 1,1-dimethyl-2,2,2-trichloroethyl, 1-methyl-

5 1-(4-biphenylyl)ethyl, 1-(3,5-di-*t*-butylphenyl)-1-methylethyl, 2-(2'- and 4'-pyridyl)ethyl, 2-(N,N-dicyclohexylcarboxamido)ethyl, *t*-butyl, 1-adamantyl, vinyl, allyl, 1-isopropylallyl, cinnamyl, 4-nitrocinnamyl, 8-quinolyl, N-hydroxypiperidinyl, alkylidithio, benzyl, *p*-methoxybenzyl, *p*-nitrobenzyl, *p*-bromobenzyl, *p*-chlorobenzyl, 2,4-dichlorobenzyl, 4-methylsulfinylbenzyl, 9-anthrylmethyl and diphenylmethyl.

10

Assisted Cleavage

Examples of assisted cleavage include 2-methylthioethyl, 2-methylsulfonylethyl, 2-(*p*-toluenesulfonyl)ethyl, [2-(1,3-dithianyl)]methyl, 4-methylthiophenyl, 2,4-dimethylthiophenyl, 2-phosphonioethyl, 2-

15 triphenylphosphonioisopropyl, 1,1-dimethyl-2-cyanoethyl, *m*-chloro-*p*-acyloxybenzyl, *p*-(dihydroxyboryl)benzyl, 5-benzisoxazolylmethyl, and 2-(trifluoromethyl)-6-chromonylmethyl.

Photolytic Cleavage

20 Examples of photolytic cleavage include *m*-nitrophenyl, 3,5-dimethoxybenzyl, *o*-nitrobenzyl, 3,4-dimethoxy-6-nitrobenzyl, and phenyl(*o*-nitrophenyl)methyl.

Urea-Type Derivatives

25 Examples of urea-type derivatives include phenothiazinyl-(10)-carbonyl derivative, N'-*p*-toluenesulfonylaminocarbonyl, and N'-phenylaminothiocarbonyl.

Miscellaneous Carbamates

Examples of miscellaneous carbamates include *t*-amyl, S-benzyl thiocarbamate, *p*-cyanobenzyl, cyclobutyl, cyclohexyl, cyclopentyl, 30 cyclopropylmethyl, *p*-decyloxybenzyl, diisopropylmethyl, 2,2-dimethoxycarbonylvinyl, *o*-(N,N-dimethylcarboxamido)benzyl, 1,1-dimethyl-3-(N,N-dimethylcarboxamido)propyl, 1,1-dimethylpropynyl, di(2-pyridyl)methyl, 2-furanylmethyl, 2-iodoethyl, isobornyl, isobutyl, isonicotinyl, *p*-(*p*'-

5 methoxyphenylazo)benzyl, 1-methylcyclobutyl, 1-methylcyclohexyl, 1-methyl-1-cyclopropylmethyl, 1-methyl-1-(3,5-dimethoxyphenyl)ethyl, 1-methyl-1-(*p*-phenylazophenyl)ethyl, 1-methyl-1-phenylethyl, 1-methyl-1-(4-pyridyl)ethyl, phenyl, *p*-(phenylazo)benzyl, 2,4,6-tri-*t*-butylphenyl, 4-(trimethylammonium)benzyl, and 2,4,6-trimethylbenzyl.

10

Examples of amides include:

Amides

N-formyl, N-acetyl, N-chloroacetyl, N-trichloroacetyl, N-trifluoroacetyl, N-phenylacetyl, N-3-phenylpropionyl, N-picolinoyl, N-3-pyridylcarboxamide, N-benzoylphenylalanyl derivative, N-benzoyl, N-*p*-phenylbenzoyl.

Assisted Cleavage

N-*o*-nitrophenylacetyl, N-*o*-nitrophenoxyacetyl, N-acetoacetyl, (N'-dithiobenzoyloxycarbonylamino)acetyl, N-3-(*p*-hydroxyphenyl)propionyl, N-3-(*o*-nitrophenyl)propionyl, N-2-methyl-2-(*o*-nitrophenoxy)propionyl, N-2-methyl-2-(*o*-phenylazophenoxy)propionyl, N-4-chlorobutyryl, N-3-methyl-3-nitrobutyryl, N-*o*-nitrocinnamoyl, N-acetylmethionine derivative, N-*o*-nitrobenzoyl, N-*o*-(benzoyloxymethyl)benzoyl, and 4,5-diphenyl-3-oxazolin-2-one.

25

Cyclic Imide Derivatives

N-phthalimide, N-dithiasuccinoyl, N-2,3-diphenylmaleoyl, N-2,5-dimethylpyrrolyl, N-1,1,4,4-tetramethyldisilylazacyclopentane adduct, 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, and 1-substituted 3,5-dinitro-4-pyridonyl.

SPECIAL – NH PROTECTIVE GROUPS

5 Examples of special NH protective groups include:

N-Alkyl and N-Aryl Amines

N-methyl, N-allyl, N-[2-(trimethylsilyl)ethoxy]methyl, N-3-acetoxypropyl, N-(1-isopropyl-4-nitro-2-oxo-3-pyrrolin-3-yl), quaternary ammonium salts, N-benzyl, N-4-methoxybenzyl, N-di(4-methoxyphenyl)methyl, N-5-dibenzosuberyl, N-triphenylmethyl, N-(4-methoxyphenyl)diphenylmethyl, N-9-phenylfluorenyl, N-2,7-dichloro-9-fluorenylmethylene, N-ferrocenylmethyl, and N-2-picollylamine N'-oxide.

Imine Derivatives

15 N-1,1-dimethylthiomethylene, N-benzylidene, N-p-methoxybenzylidene, N-diphenylmethylene, N-[(2-pyridyl)mesityl]methylene, and N-(N',N'-dimethylaminomethylene).

PROTECTION FOR THE CARBONYL GROUP

20

Acyclic Acetals and Ketals

Examples of acyclic acetals and ketals include dimethyl, bis(2,2,2-trichloroethyl), dibenzyl, bis(2-nitrobenzyl) and diacetyl.

25

Cyclic Acetals and Ketals

Examples of cyclic acetals and ketals include 1,3-dioxanes, 5-methylene-1,3-dioxane, 5,5-dibromo-1,3-dioxane, 5-(2-pyridyl)-1,3-dioxane, 1,3-dioxolanes, 4-bromomethyl-1,3-dioxolane, 4-(3-but enyl)-1,3-dioxolane, 4-phenyl-1,3-dioxolane, 4-(2-nitrophenyl)-1,3-dioxolane, 4,5-dimethoxymethyl-1,3-dioxolane, O,O'-phenylenedioxy and 1,5-dihydro-3H-2,4-benzodioxepin.

Acyclic Dithio Acetals and Ketals

5 Examples of acyclic dithio acetals and ketals include S,S'-dimethyl, S,S'-diethyl, S,S'-dipropyl, S,S'-dibutyl, S,S'-dipentyl, S,S'-diphenyl, S,S'-dibenzyl and S,S'-diacetyl.

Cyclic Dithio Acetals and Ketals

10 Examples of cyclic dithio acetals and ketals include 1,3-dithiane, 1,3-dithiolane and 1,5-dihydro-3H-2,4-benzodithiepin.

Acyclic Monothio Acetals and Ketals

15 Examples of acyclic monothio acetals and ketals include O-trimethylsilyl-S-alkyl, O-methyl-S-alkyl or -S-phenyl and O-methyl-S-2-(methylthio)ethyl.

Cyclic Monothio Acetals and Ketals

Examples of cyclic monothio acetals and ketals include 1,3-oxathiolanes.

20 MISCELLANEOUS DERIVATIVES

O-Substituted Cyanohydrins

Examples of O-substituted cyanohydrins include O-acetyl, O-trimethylsilyl, O-1-ethoxyethyl and O-tetrahydropyranyl.

25

Substituted Hydrazones

Examples of substituted hydrazones include N,N-dimethyl and 2,4-dinitrophenyl.

30 Oxime Derivatives

Examples of oxime derivatives include O-methyl, O-benzyl and O-phenylthiomethyl.

5

Imines**Substituted Methylene Derivatives, Cyclic Derivatives**

Examples of substituted methylene and cyclic derivatives include oxazolidines, 1-methyl-2-(1'-hydroxyalkyl)imidazoles, N,N'-dimethylimidazolidines, 10 2,3-dihydro-1,3-benzothiazoles, diethylamine adducts, and methylaluminum bis(2,6-di-*t*-butyl-4-methylphenoxy)(MAD)complex.

MONOPROTECTION OF DICARBONYL COMPOUNDS

15 **Selective Protection Of α -and β -Diketones**

Examples of selective protection of α -and β -diketones include enamines, enol acetates, enol ethers, methyl, ethyl, *i*-butyl, piperidinyl, morpholinyl, 4-methyl-1,3-dioxolanyl, pyrrolidinyl, benzyl, S-butyl, and trimethylsilyl.

20 **Cyclic Ketals, Monothio and Dithio Ketals**

Examples of cyclic ketals, monothio and dithio ketals include bismethylenedioxy derivatives and tetramethylbismethylenedioxy derivatives.

PROTECTION FOR THE CARBOXYL GROUP

25

Esters**Substituted Methyl Esters**

Examples of substituted methyl esters include 9-fluorenylmethyl, 30 methoxymethyl, methylthiomethyl, tetrahydropyranyl, tetrahydrofuranyl, methoxyethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, benzyloxymethyl, phenacyl, *p*-

5 bromophenacyl, α -methylphenacyl, *p*-methoxyphenacyl, carboxamidomethyl, and N-phthalimidomethyl.

2-Substituted Ethyl Esters

Examples of 2-substituted ethyl esters include 2,2,2-trichloroethyl,

10 2-haloethyl, ω -chloroalkyl, 2-(trimethylsilyl)ethyl, 2-methylthioethyl, 1,3-dithianyl-2-methyl, 2-(*p*-nitrophenylsulfonyl)ethyl, 2-(*p*-toluenesulfonyl)ethyl, 2-(2'-pyridyl)ethyl, 2-(diphenylphosphino)ethyl, 1-methyl-1-phenylethyl, *t*-butyl, cyclopentyl, cyclohexyl, allyl, 3-buten-1-yl, 4-(trimethylsilyl)-2-buten-1-yl, cinnamyl, α -methylcinnamyl, phenyl, *p*-(methylmercapto)phenyl and benzyl.

15

Substituted Benzyl Esters

Examples of substituted benzyl esters include triphenylmethyl,

diphenylmethyl, bis(*o*-nitrophenyl)methyl, 9-anthrylmethyl, 2-(9,10-dioxo)anthrylmethyl, 5-dibenzosuberyl, 1-pyrenylmethyl, 2-(trifluoromethyl)-6-

20 chromylmethyl, 2,4,6-trimethylbenzyl, *p*-bromobenzyl, *o*-nitrobenzyl, *p*-nitrobenzyl, *p*-methoxybenzyl, 2,6-dimethoxybenzyl, 4-(methylsulfinyl)benzyl, 4-sulfonylbenzyl, piperonyl, 4-picoly and *p*-P-benzyl.

Silyl Esters

25 Examples of silyl esters include trimethylsilyl, triethylsilyl, *t*-butyldimethylsilyl, *i*-propyldimethylsilyl, phenyldimethylsilyl and di-*t*-butylmethysilyl.

Activated Esters

Examples of activated esters include thiols.

30

Miscellaneous Derivatives

5 Examples of miscellaneous derivatives include oxazoles, 2-alkyl-1,3-oxazolines, 4-alkyl-5-oxo-1,3-oxazolidines, 5-alkyl-4-oxo-1,3-dioxolanes, ortho esters, phenyl group and pentaaminocobalt(III) complex.

Stanny Esters

10 Examples of stanny esters include triethylstanny and tri-*n*-butylstanny.

AMIDES AND HYDRAZIDES

Amides

15 Examples of amides include N,N-dimethyl, pyrrolidinyl, piperidinyl, 5,6-dihydrophenanthridinyl, *o*-nitroanilides, N-7-nitroindolyl, N-8-Nitro-1,2,3,4-tetrahydroquinolyl, and *p*-P-benzenesulfonamides.

Hydrazides

20 Examples of hydrazides include N-phenyl and N,N'-diisopropyl.


The compounds of the invention can be prepared according to the methods described in the next section.

5 C. Synthesis

The compounds of the invention can be prepared according to traditional synthetic organic methods and matrix or combinatorial chemistry methods, as shown in Schemes 1-7 below and in Examples 1-34. A person of ordinary skill will be 10 aware of variations and adaptations of the schemes and examples provided to achieve the compounds of the invention. One skilled in the art will recognize that synthesis of the compounds of the present invention may be effected by purchasing intermediate or protected intermediate compounds described in any of the schemes disclosed herein.

15

Compounds of formula I may be prepared according to the processes outlined in Schemes 1 through 5.




20

Scheme 1

5 Compounds of formula V and formula VII, wherein the substituents are as defined in formula I, may be prepared according to the process outlined in Scheme 1. Specifically compounds of formula II and formula III react to provide a compound of formula IV in Step A upon treatment with Pd catalyst such as $Pd_2(dba)_3$, a ligand such as triphenylphosphine, or *t*-tributylphosphine, in presence of a base, for example cesium carbonate, potassium carbonate or the like in a solvent such as dioxane, or THF. In a preferred embodiment the compounds of formula II and III react in presence of $Pd_2(dba)_3$, *t*-tributylphosphine, cesium carbonate in dioxane to afford a compound of formula IV. In Step B a compound of formula IV upon treatment with an appropriately Ga-H, where Ga is the defined substituents Ga in formula I, in the presence of a reductant such as $NaBH_4$, or $NaB(OAc)_3H$ in acidic condition, for example HOAc, in methylene chloride provides a compound of formula V. In a preferred embodiment the reductant is $NaB(OAc)_3H$.

10 A compound of formula VI may be obtained, in Step C, by reacting a compound of formula IV with an appropriately amount of Ga-H, where Ga is the defined substituents Ga in formula I. The reaction condition is same as that of for a compound of formula V except the amount of Ga-H is a half of that for a compound of formula V.

15 A compound of formula VII may be obtained, in Step D, by treating a compound of formula of VI with Gb-H where Gb is the defined substituents Gb in formula I, in the presence of a reductant such as $NaBH_4$, or $NaB(OAc)_3H$ in acidic condition, for example in HOAc, in methylene chloride. A compound of formula VII may also be obtained, in Step D, by treating hydroxyamine, or alkylated hydroxyamine, in presence of a base such as cesium carbonate, potassium carbonate, sodium carbonate or the like in a solvent such as methanol, or ethanol. In a preferred embodiment a compound of formula VI is treated with hydroxyamine, and sodium carbonate in ethanol to afford a compound of formula VII.



Scheme 2

Compounds of formula X and formula XII, wherein the substituents are as

defined in formula I, may be prepared according to the process outlined in Scheme

10 2. Specifically a compound of formula VIII is converted to a compound of formula IX in Step E upon treatment with thionyl chloride, or oxalyl chloride in chloroform, dichloromethane, or dichloroethane at room temperature or an elevated temperature. In a preferred embodiment the compounds of formula VIII reacts with thionyl chloride in chloroform at 50-70 °C providing a compound of formula IX. In


15 Step F a compound of formula IX upon treatment with an appropriately Ga-H, where Ga is the defined substituents Ga in formula I, in the presence of a base, for example cesium carbonate, potassium carbonate, sodium carbonate or the like in a solvent such as acetone, or acetonitrile provides a compound of formula X. In a preferred embodiment, the base is potassium carbonate and the solvent is

20 acetonitrile.

A compound of formula of IX in Step G reacts with phthalimide, in presence of a base, for example cesium carbonate, potassium carbonate, sodium carbonate or the like in DMF to afford an intermediate. In a preferred embodiment the base is potassium carbonate. The intermediate may react with hydrazine in a mixture of 25 methanol and THF at elevated temperature preferably at the boiling point of the mixed solvents providing a compound of formula XI.

5 A compound of formula XI is converted to a compound of formula XII in Step H upon treatment with an appropriately isothiourea, or alkylated isothiourea in pyridine at reflux temperature. In a preferred embodiment the compound of formula XI reacts with 2-thio-2-imidazoline in pyridine at reflux providing a compound of formula IX.

10



Scheme 3

Compounds of formula XV and formula XVIII, wherein the substituents are as


15 defined in formula I, may be prepared according to the process outlined in Scheme 3. Specifically a compound of formula XIII is converted to a compound of formula XV in Step I by reacting with a compound of formula XIV in the presence of a base, for example sodium *t*-butoxide, potassium *t*-butoxide, cesium carbonate, potassium carbonate, sodium carbonate or the like in a solvent such as methanol, or ethanol. In
20 a preferred embodiment, the base is *t*-butoxide and the solvent is ethanol.

A compound of formula of XIII in Step J reacts with a compound of formula of XVI, wherein Z_2 is nitrogen, in presence of tetrabutylammonium hydrogen sulfate, and a base for example cesium carbonate, potassium carbonate, or sodium hydroxide in a solvent such as benzene, or toluene to afford a compound of formula

5 of XVII. In a preferred embodiment the base is sodium hydroxide, and the solvent is benzene.

A compound of formula XVIII may be obtained in Step K by treating a compound of formula XVII with an appropriately Ga-H, where Ga is the defined substituents Ga in formula I, in the presence of a reductant such as NaBH_4 , or


10 NaB(OAc)₃H in acidic condition, for example HOAc, in methylene chloride. In a preferred embodiment the reductant is NaB(OAc)₃H.



15

Scheme 4

Compounds of formula XX wherein the substituents are as defined in formula I, may be prepared according to the process outlined in Scheme 4. Specifically a compound of formula XIX is converted to a compound of formula XX in step L upon treatment with amine NHR_c , which is R_c is the defined substituents R_c in compounds of formula I, Pd catalyst such as $\text{Pd}_2(\text{dba})_3$, a ligand such as triphenylphosphine, or *t*-tributylphosphine, in presence of a base, for example cesium carbonate, potassium carbonate, or the like in a solvent such as dioxane, or THF. In a preferred embodiment the compound of formula XIX reacts with amine NHR_c in the presence of $\text{Pd}_2(\text{dba})_3$, *t*-tributylphosphine, cesium carbonate in dioxane to afford a compound of formula XX.




Scheme 5

A compound of formula XXI in Step M is treated with an appropriately

10 thiourea, or alkylated thiourea, in a solvent such as methanol or ethanol at reflux temperature for certain time like 1 or 2 hour. Subsequently a base such as triethylamine, cesium carbonate, potassium carbonate, or the like was treated providing a compound of formula XXII. In a preferred embodiment the compound of formula XXI reacts with 2-imidazolidinethione in ethanol at reflux followed by treating


15 triethylamine to afford a compound of formula XXII.



Scheme 6

A compound of formula XXIII in Step N is treated with an appropriately

20 dialkylamino-alkyl-thiol and a base such as sodium hydride in the presence of a catalyst such as $\text{Pd}(\text{PPh}_3)_4$ in a solvent such as n-butanol at reflux temperature for a certain time like 6 hours providing a compound of formula XXIV.



5

Scheme 7

A compound of formula XXV in Step O is treated with an appropriately dialkylamino-alkyl-halogen and a base such as potassium *t*-butoxide in a solvent such as methanol or ethanol at reflux temperature for a certain time like 18 or 24 hours 10 providing a compound of formula XXVI.

5 D. Formulation, Administration, and Therapy

The disclosed compounds, alone or in combination (with, for example, a histamine H₁ receptor antagonist), are useful for treating or preventing neurologic disorders including sleep/wake and arousal/vigilance disorders (e.g. insomnia and jet lag), attention deficit hyperactivity disorders (ADHD), learning and memory disorders, cognitive dysfunction, migraine, neurogenic inflammation, dementia, mild cognitive impairment (pre-dementia), Alzheimer's disease, epilepsy, narcolepsy, eating disorders, obesity, motion sickness, vertigo, schizophrenia, substance abuse, bipolar disorders, manic disorders and depression, as well as other histamine H₃ receptor mediated disorders such as upper airway allergic response, asthma, itch, nasal congestion and allergic rhinitis in a subject in need thereof.

1. Formulation and Administration

The compounds or compositions of the invention may be formulated and administered to a subject by any conventional route of administration, including, but not limited to, intravenous, oral, subcutaneous, intramuscular, intradermal and parenteral administration. The quantity of the compound which is effective for treating each condition may vary, and can be determined by one of ordinary skill in the art.

For use in medicine, the salts of the compounds of this invention refer to non-toxic "pharmaceutically acceptable salts." Other salts may, however, be useful in the preparation of compounds according to this invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds include acid addition salts which may, for example, be formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compounds of the invention carry an acidic moiety, suitable

5 pharmaceutically acceptable salts thereof may include alkali metal salts, e.g., sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts.

Thus, representative pharmaceutically acceptable salts include the following: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate,

10 bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, 15 methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, oleate, pamoate (embonate), palmitate, pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, sulfate, subacetate, succinate, tannate, tartrate, teoclinate, tosylate, triethiodide and valerate.

20 The present invention includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the

compounds which are readily convertible *in vivo* into the required compound. Thus, in the methods of treatment of the present invention, the term "administering" shall encompass the treatment of the various disorders described with the compound

25 specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound *in vivo* after administration to the patient. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985. In addition to salts, the invention provides the esters, amides, and 30 other protected or derivatized forms of the described compounds.

Where the compounds according to this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds possess

- 5 two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with
- 10 water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.

The present invention also provides pharmaceutical compositions comprising one or more compounds of this invention in association with a pharmaceutically acceptable carrier and optionally additional pharmaceutical agents such as H₁ antagonists or SSRIs. Preferably these compositions are in unit dosage forms such as pills, tablets, caplets, capsules (each including immediate release, timed release and sustained release formulations), powders, granules, sterile parenteral solutions or suspensions (including syrups and emulsions), metered aerosol or liquid sprays,

- 15
- 20
- 25
- 30

drops, ampoules, autoinjector devices or suppositories; for oral parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. Alternatively, the composition may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tabletting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily

5 subdivided into equally effective dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 5 to about 1000 mg of the active ingredient of the present invention. Examples include 5 mg, 7 mg, 10 mg, 15 mg, 20 mg, 35 mg, 50 mg, 75 mg, 100 mg, 120 mg, 150 mg, and so on. The tablets or pills

10 of the disclosed compositions can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be septed by an enteric layer which serves to resist disintegration in the stomach and permits the

15 inner component to pass intact into the duodenum or to be delayed in release. A variety of material can be used for such enteric layers or coatings, such materials including a number of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

20 The liquid forms in which the compounds and compositions of the present invention may be incorporated for administration orally or by injection include, aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable

25 dispersing or suspending agents for aqueous suspensions, include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

Where the processes for the preparation of the compounds according to the

30 invention give rise to mixture of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be

- 5 resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by
- 10 chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.

Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of

- 15 two, three or four times daily. Furthermore, compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

20

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can

- 25 also be incorporated into the mixture. Suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar,
- 30 bentonite, xanthan gum and the like.

The compound of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar

5 vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are

10 coupled. The compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residue. Furthermore, the compounds of the present invention may be
15 coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.

20 Compounds of this invention may be administered in any of the foregoing compositions and according to dosage regimens established in the art whenever treatment of ADHD is required.

The daily dosage of the products may be varied over a wide range from 1 to
25 1,000 mg per adult human per day. For oral administration, the compositions are preferably provided in the form of tablets containing 1.0, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 250 and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the subject to be treated. An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.01 mg/kg to about 20 mg/kg of body weight
30 per day. Preferably, the range is from about 0.02 mg/kg to about 10 mg/kg of body weight per day, and especially from about 0.05 mg/kg to about 10 mg/kg of body weight per day. The compounds may be administered on a regimen of 1 to 4 times per day.

5

Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound used, the mode of administration, the strength of the preparation, the mode of administration, and the advancement of the disease condition. In addition, factors associated with the particular patient being 10 treated, including patient age, weight, diet and time of administration, will result in the need to adjust dosages.

2. Combination Therapy


The disclosed compounds are useful in combination with other therapeutic 15 agents, including H₁ receptor antagonists, H₂ receptor antagonists, and neurotransmitter modulators such as SSRIs and non-selective serotonin re-uptake inhibitors (SSRIs).

Methods are known in the art for determining effective doses for therapeutic and prophylactic purposes for the disclosed pharmaceutical compositions or the 20 disclosed drug combinations, whether or not formulated in the same composition. For therapeutic purposes, the term "jointly effective amount" as used herein, means that amount of each active compound or pharmaceutical agent, alone or in combination, that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor 25 or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated. For prophylactic purposes (i.e., inhibiting the onset or progression of a disorder), the term "jointly effective amount" refers to that amount of each active compound or pharmaceutical agent, alone or in combination, that inhibits in a subject the onset or progression of a disorder as being sought by a 30 researcher, veterinarian, medical doctor or other clinician, the delaying of which disorder is mediated, at least in part, by the modulation of one or more histamine receptors. Thus, the present invention provides combinations of two or more drugs wherein, for example, (a) each drug is administered in an independently

- 5 therapeutically or prophylactically effective amount; (b) at least one drug in the combination is administered in an amount that is sub-therapeutic or sub-prophylactic if administered alone, but is therapeutic or prophylactic when administered in combination with the second or additional drugs according to the invention; or
- 10 (c) both drugs are administered in an amount that is sub-therapeutic or sub-prophylactic if administered alone, but are therapeutic or prophylactic when administered together. Combinations of three or more drugs are analogously possible. Methods of combination therapy include co-administration of a single formulation containing all active agents; essentially contemporaneous administration of more than one formulation; and administration of two or more active agents
- 15 separately formulated.

5 E. Examples

Example 1



1-[4-(4-Pyrrolidin-1-ylmethyl-phenyl)-thiophen]-2-ylmethyl]-pyrrolidine

10 $K_i = 9.0 \text{ nM}$


Step A 2-Formyl-4-(4-formylphenyl)-thiophene

5-Formyl-2-thiophene boronic acid (1 equiv, 312 mg), 4-bromobenzaldehyde (1 equiv, 312 mg), $\text{Pd}_2(\text{dba})_3$ (1.5% equiv, 28 mg), $t\text{-Bu}_3\text{P}$ (3.5% equiv, 15 mg), and cesium carbonate (1.3 g) in dioxane (2 mL) was stirred at 80 °C for 24 h. After concentration, the mixture was purified by preparative TLC (20% EtOAc in Hexanes) to afford the title compound (40 mg).

Step B

2-Formyl-4-(4-formylphenyl)-thiophene (1 equiv, 33 mg) mixed with 20 pyrrolidine (2.6 equiv, 33 μL), HOAc (4 equiv, 35 μL), and $\text{NaBH}(\text{OAc})_3$ (2.6 equiv, 103 mg) in methylene chloride (5 mL) was stirred at room temperature for 16 h. After concentration, the mixture was purified by preparative TLC (20% EtOAc in methylene chlorides) to afford the title compound (10 mg). ^1H NMR (400 MHz, CDCl_3) δ 7.45 (d, $J = 8.3 \text{ Hz}$, 2H), 7.25 (d, $J = 8.3 \text{ Hz}$, 2H), 7.06 (d, $J = 3.6 \text{ Hz}$, 1H), 25 6.22 (d, $J = 3.6 \text{ Hz}$, 1H), 3.76 (s, 2H), 3.58 (s, 2H), 2.51 (m, 8H), 1.74 (m, 8H).

Example 2




5 1-[(4-(4-Pyrrolidin-1-ylmethyl-phenyl)-furan)-2-ylmethyl]-pyrrolidine
 $K_i = 0.41$ nM

The title compound was prepared starting from 5-formyl-2-furan boronic acid and 4-bromobenzaldehyde by the same method described in Example 1.

10 ^1H NMR (400 MHz, CDCl_3) δ 7.55 (d, $J = 8.3$ Hz, 2H), 7.27 (d, $J = 8.3$ Hz, 2H), 6.50 (d, $J = 3.3$ Hz, 1H), 6.22 (d, $J = 3.3$ Hz, 1H), 3.69 (s, 2H), 3.62 (s, 2H), 2.55 (m, 8H), 1.74 (m, 8H).


Example 3



1-((4-(4-Pyrrolidin-1-ylmethyl-thiophen)-2-ylthiophen)-2-ylmethyl)-pyrrolidine
 $K_i = 1.4$ nM

The title compound was prepared starting from 5-formyl-2-thiophene
20 boronic acid and 2-bromo-5-formylthiophene by the same method described in
Example 1. ^1H NMR (400 MHz, CDCl_3) δ 7.06 (d, $J = 3.6$ Hz, 2H), 6.72 (s, $J = 3.6$ Hz, 2H), 3.65 (s, 4H), 2.48 (s, 8H), 1.64 (m, 8H).

Example 4




1-[(2-(4-Pyrrolidin-1-ylmethyl-phenyl)-thiophen)-3-ylmethyl]-pyrrolidine

5 $K_i = 9.0 \text{ nM}$

The title compound was prepared starting from 2-formyl-3-thiophene boronic acid and 4-bromobenzaldehyde by the same method described in Example 1. ^1H NMR (400 MHz, CDCl_3) δ 7.47 (m, 2H), 7.37 (m, 2H), 7.21 (d, 1H), 6.16 (m, 1H),
10 3.55 (s, 2H), 3.52 (s, 2H), 2.44 (m, 8H), 1.70 (m, 8H).

Example 5




1-[(3-(4-Pyrrolidin-1-ylmethyl-phenyl)-thiophen)-2-ylmethyl]-pyrrolidine

15 $K_i = 63 \text{ nM}$

The title compound was prepared starting from 3-formyl-2-thiophene boronic acid and 4-bromobenzaldehyde by the same method described in Example 1. ^1H NMR (400 MHz, CDCl_3) δ 7.26 (m, 4H), 6.50 (d, $J = 5.1 \text{ Hz}$, 1H), 6.22 (d, $J = 5.1 \text{ Hz}$,
20 1H), 3.77 (s, 2H), 3.57 (s, 2H), 2.48 (m, 8H), 1.71 (m, 8H).

Example 6




1-[4-(4-Pyrrolidin-1-ylmethyl-phenoxy)-benzyl]-pyrrolidine

5 $K_i = 0.50 \text{ nM}$

A suspension of 4,4-oxydibenzyl chloride (135 mg), pyrrolidine (107 mg), potassium carbonate (212 mg) and tetrabutylammonium iodide (5 mg) in acetonitrile (10 mL) was heated at reflux for 1 h. Then the solvent was evaporated. The residue was dissolved in methylene chloride, washed with saturated aqueous sodium bicarbonate, dried (sodium sulfate), and concentrated providing the title compound (168 mg). ^1H NMR (400 MHz, CDCl_3) δ 7.30 (d, $J = 10 \text{ Hz}$, 4H), 7.27 (d, $J = 10 \text{ Hz}$, 4H), 3.54 (s, 4H), 2.55 (m, 8H), 1.80 (m, 8H).

10 Example 7

15




1-[4-(4-Piperidin-1-ylmethyl-phenoxy)-benzyl]-piperidine

$K_i = 0.66 \text{ nM}$

A suspension of 4,4-oxydibenzyl chloride (117 mg), piperidine (111 mg), potassium carbonate (180 mg) and tetrabutylammonium iodide (5 mg) in acetonitrile (10 mL) was heated at reflux for 1 h. Then the solvent was evaporated. The residue was dissolved in methylene chloride, washed with saturated aqueous sodium bicarbonate, dried (sodium sulfate), and concentrated providing the title compound (110 mg). $M + H^+$ (calculated): 365.3; $M + H^+$ (found): 365.1. ^1H NMR (400 MHz, $\text{MeOH-}d_6$) δ 7.21 (d, $J = 12 \text{ Hz}$, 4H), 6.85 (d, $J = 12 \text{ Hz}$, 4H), 3.40 (s, 4H), 2.33 (m, 8H), 1.50 (m, 8H).

5

Example 8



1-[4-(4-Pyrrolidin-1-ylmethyl-benzenesulfonyl)-benzyl]-pyrrolidine

$K_i = 2.5 \text{ nM}$

10

Step A 4,4'-sulfonyldibenzyl chloride


A solution of 4,4'-sulfonyldibenzyl alcohol (278 mg), and thionyl chloride (0.8 mL) in chloroform (10 mL) was heated at reflux for 2 h. Evaporation of solvent 15 gave the title compound which was used without further purification.

Step B

A suspension of 4,4'-sulfonyldibenzyl chloride (157 mg), pyrrolidine (107 mg), 20 potassium carbonate (212 mg) and tetrabutylammonium iodide (5 mg) in acetonitrile (10 mL) was heated at reflux for 1 h. Then the solvent was evaporated. The residue was dissolved in methylene chloride, washed with saturated aqueous sodium bicarbonate, dried (sodium sulfate), and concentrated. Preparative thin layer silica gel chromatography of the residue (10% methanol/dichloromethane) provided the 25 title compound (110 mg). ^1H NMR (400 MHz, CDCl_3) δ 7.86 (d, $J = 8.5 \text{ Hz}$, 4H), 7.46 (d, $J = 8.5 \text{ Hz}$, 4H), 3.61 (s, 4H), 2.45 (m, 8H), 1.75 (m, 8H).

5

Example 9




1-[4-(4-Pyrrolidin-1-ylmethyl-benzyl)-benzyl]-pyrrolidine

 $K_i = 2.0 \text{ nM}$

10

The title compound was prepared starting from 4,4'-methylenedibenzyl chloride and pyrroline by the same method described in example 6. ^1H NMR (400 MHz, CDCl_3) δ 7.17 (d, $J = 8.0 \text{ Hz}$, 4H), 7.05 (d, $J = 8.0 \text{ Hz}$, 4H), 3.86 (s, 2H), 2.42 (m, 8H), 1.69 (m, 8H).

5 Example 10




1-[4-(4-imidazo-1-ylmethyl-phenoxy)-benzyl]-imidazole

 $K_i = 151 \text{ nM}$

10 The title compound was prepared starting from 4,4'-oxydibenzyl chloride and imidazole by the same method described in example 6. ^1H NMR (400 MHz, CDCl_3) δ 7.63 (s, 2H), 7.15 (d, $J = 8.6$ Hz, 4H), 6.99 (s, 2H), 6.84 (d, $J = 8.5$ Hz, 2H), 5.07 (s, 4H).

15 Example 11




1-[4-(4-imidazo-1-ylmethyl-benzyl)-benzyl]-imidazole

 $K_i = 150 \text{ nM}$

20 The title compound was prepared starting from 4,4'-methylenedibenzyl chloride and imidazole by the same method described in example 6. ^1H NMR (400 MHz, CDCl_3) δ 7.45 (s, 2H), 7.10 (d, $J = 8.0$ Hz, 4H), 6.88 (m, 6H), 6.57 (s, 2H), 5.02 (s, 4H), 3.90 (s, 2H).

25 Example 12




[4-(N,N'-dimethyl-isothiourea)-methyl-phenoxy]-benzyl]-N,N'-dimethyl-isothiourea

5 $K_i = 85 \text{ nM}$

A mixture of 4,4'-oxydibenzyl chloride (1equiv, 67 mg), and N, N'-dimethyl-thiourea (2equiv, 52 mg) in ethanol (10 mL) was heated at reflux for 8 h. Then the solvent was evaporated to provide the title compound 2HCl salt in quantitative yield.

10 ^1H NMR (400 MHz, MeOD- d_4) δ 7.48 (m, 4H), 7.04 (d, 4H), 4.53 (m, 4H), 3.07 (m, 12H).

Example 13




15 [4-(N-methyl-isothiourea)-methyl-phenoxy]-benzyl]-N-methyl-isothiourea
 $K_i = 629 \text{ nM}$

The title compound 2HCl salt was prepared starting from 4,4'-oxydibenzyl chloride and N-methyl-thiourea by the same method described in Example 12. ^1H

20 NMR (400 MHz, MeOD- d_4) δ 7.46 (m, 4H), 6.99 (m, 4H), 4.49 (m, 4H), 3.00 (m, 6H),

Example 14




2-[4-(4-(2-imidazolidin)-2-ylthiomethyl-phenoxy)-benzyl-thio]-2-imidazolidine

25 4,4'-Oxydibenzyl chloride (67 mg) and -2-imidazolidinethion (51 mg) in ethanol (10 mL) were reflux for 2 hour. After cooled down, ether was added and precipitate

5 was collected as the title compound 2HCl salts (80 mg). ^1H NMR (400 MHz, MeOD-
 d_4) δ 7.48 (d, J = 8.7 Hz, 4H), 7.04 (d, J = 8.7 Hz, 4H), 4.53 (s, 4H), 4.00 (s, 8H).


Example 15



10 2-[4-(4-(2-Thiazolin)-2-ylthiomethyl-phenoxy)-benzyl-thio]-2-thiazoline
 K_i = 2574 nM

15 To a mixture of 4,4'-oxydibenzyl chloride (1 equiv, 134 mg), and 2-thio-
thiazoline (2 equiv, 119 mg) in ethanol (1 mL) was added NaOH (2.5 equiv, 50 mg)
in H_2O (2 mL). After heated at 80 °C for 2 h. Concentration and preparative TLC
(EtOAc in hexanes) provide the title compound (100 mg). ^1H NMR (400 MHz, CDCl_3)
 δ 7.24 (d, J = 6.7 Hz, 4H), 6.86 (d, J = 6.7 Hz, 4H), 4.25 (s, 4H), 4.15 (t, J = 8.0 Hz,
4H), 3.30 (t, J = 8.0 Hz, 4H).

20 Example 16




25 2-[4-(4-(1-Methyl-imidazo)-2-ylthiomethyl-phenoxy)-benzyl-thio]-1-methyl-
imidazole

K_i = 792 nM

The title compound was prepared starting from 4,4'-oxydibenzyl chloride and
1-methyl-2-thio-imidazole by the same method described in Example 15. ^1H NMR
(400 MHz, CDCl_3) δ 7.14 (m, 6H), 6.90 (m, 6H), 4.19 (s, 4H), 3.38 (m, 12H).

5

Example 17



2-[4-(4-(2-imidazolidin)-2-ylaminomethyl-phenoxy)-benzyl-amino]-2-imidazolidine

$K_i = 344$ nM

10

Step A 4,4'-oxydibenzyl amine


The suspension of 4,4'-oxydibenzyl chloride (2.5g), phthalimide (2.96 g), and potassium (6.76 g) was vigorously stirred at room temperature for 16 h. Water (100 mL) was added, and the precipitate was filtered. The solid was collected, dissolved in methylene chloride (200 mL), washed with 1N NaOH (2 X 100 mL), and dried. After concentration, the crude intermediate was obtained. This intermediate (1.22g, 2.5 mmol) mixed with hydrazine (0.74 mL) in MeOH/THF (16 mL/16 mL) was heated at reflux. After overnight, the suspension was cooled, and filtered. The solid was washed with methanol. The filtrate was concentrated. The resulting solid was partitioned between methylene chloride (200 mL) and 1N NaOH (2 X 100 mL), washed, and dried. After concentration, the title compound was obtained (500 mg).

Step B

The 4,4'-oxydibenzyl amine (22 mg) and 2-thio-2-imidazolidine were mixed in pyridine (4 mL). The mixture was heated at 100 °C for overnight. Then solvent was evaporated. Preparative TLC (EtOAc in hexanes) of the residue provided the title compound (16 mg). ^1H NMR (400 MHz, MeOD- d_4) δ 7.38 (m, 4H), 7.02 (m, 4H), 4.25 (s, 4H), 3.77 (s, 8H).

5

Example 18




1-[4-(3,5-Dichloro-phenoxy)-benzyl]-pyrrolidine

The title compound was prepared starting from 4-(3,5-dichloro-10 phenoxy)-benzaldehyde and pyrrolidine by the same method (step B) described in Example 1. ^1H NMR (400 MHz, CDCl_3) δ 7.22 (t, J = 7.8 Hz, 1H), 7.07 (d, J = 7.6 Hz, 1H), 6.96 (m, 2H), 6.81 (m, 1H), 6.76 (m, 2H), 3.52 (s, 2H), 2.45 (m, 4 H), 1.70 (m, 4H).

15

Example 19



1-[4-(4-Bromo-benzyloxy)-benzyl]-pyrrolidine

Step A 4-Hydroxybenzyl-pyrrolidine


20 The title compound was prepared starting from 4-hydroxybenzaldehyde and pyrrolidine by the same method (step B) described in Example 1.

Step B

The mixture of 4-hydroxybenzyl-pyrrolidine (177 mg), 4-bromo-benzylchloride (205 mg), and $t\text{-Bu}_3\text{ONa}$ (192 mg) in ethanol (10 mL) was heated at 80°C for 25 overnight. Concentration and preparative TLC provided the title compound (200 mg). ^1H NMR (400 MHz, CDCl_3) δ 7.50 (d, J = 6.5 Hz, 2H), 7.32 (d, J = 6.5 Hz, 2H), 7.25 (d, J = 6.5 Hz, 2H), 6.90 (d, J = 6.5 Hz, 2H), 2.84 (s, 2H), 2.50 (m, 4H), 1.42 (m, 4H).

5

Example 20



1-[4-(4-Pyrrolidin-1-ylmethyl-phenoxyethyl)-benzyl]-1H-pyrrole

10 $K_i = 16 \text{ nM}$

step A 1-(4-Chloromethyl-benzyl)-pyrrole


The mixture of pyrrole (0.67g), triethylamine (0.75g), DMAP (0.09g), and 4-chloromethyl-benzoyl chloride (1.399g) was stirred at room temperature for 15 overnight. After concentration, column chromatography (EtOAc in hexanes) provided the desired intermediate. This intermediate (110 mg) in THF (2 mL) was treated with $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (0.5 mL) and NaBH_4 (76 mg). After being heated at 80°C for overnight, the reaction was quenched by NaHCO_3 saturated solution. The organic layer was concentrated and preparative TLC to provide the title compound.

20 Step B

The title compound was prepared starting from 1-(4-chloromethyl-benzyl)-pyrrole and 4-hydroxybenzyl-pyrrolidine by the same method described in Example 19. ^1H NMR (400 MHz, $\text{MeOD}-d_4$) δ 7.18 (m, 2H), 6.99 (m, 2H), 6.59 (t, $J = 2.1 \text{ Hz}$, 2H), 5.97 (t, $J = 2.1 \text{ Hz}$, 2H), 4.99 (s, 2H), 3.55 (s, 2H), 2.41 (m, 4H), 1.70 (m, 4H).

25

Example 21




1-(4-Pyrrolidin-1-ylmethyl-benzyl)-1H-pyrrole

5

The title compound was prepared starting from 1-(4-chloromethyl-benzyl)-pyrrole (preparation in example 20 step A) and pyrrolidine by the same method reported in Example 19 step B. ^1H NMR (400 MHz, MeOD- d_4) δ 7.26 (m, 2H), 7.15 (m, 2H), 7.05 (m, 2H), 6.85 (m, 2H), 6.57 (t, J = 2.1 Hz, 2H), 5.96 (t, J = 2.1 Hz, 2H), 4.98 (s, 2H), 4.92 (s, 2H), 3.50 (s, 3H), 2.50 (m, 2H), 1.70 (m, 2H).

Example 22



Benzyl-(4-pyrrolidin-1-ylmethyl-phenyl)-amine

15

Step A 4-Bromobenzyl-pyrrolidine


The title compound was prepared starting from 4-bromobenzaldehyde and pyrrolidine by the same method (step B) described in Example 1.

Step B

20 The mixture of 4-bromobenzyl-pyrrolidine (1 equiv, 120 mg), $\text{Pd}_2(\text{dba})_3$ (2.0% equiv, 9.15 mg), $t\text{-Bu}_3\text{P}$ (1.6% equiv, 1.6 mg), benzylamine (1 equiv, 53.6 mg) and $\text{NaO}t\text{Bu}_3$ (1.5 equiv, 72 mg) in toluene (5 mL) was heated at 70°C for 8 h. Concentration and preparative TLC provided the title compound (80 mg). ^1H NMR (400 MHz, CDCl_3) δ 7.36 (m, 5H), 7.17 (d, J = 8.4 Hz, 2H), 6.62 (d, J = 8.4 Hz, 2H), 4.34 (s, 2H), 3.60 (s, 2H), 2.59 (m, 4H), 1.83 (m, 4H).

5

Example 23



Benzyl-bis-(4-pyrrolidin-1-ylmethyl-phenyl)-amine

 $K_i = 15 \text{ nM}$

10

Step A 4-Bromobenzyl-pyrrolidine


The title compound was prepared starting from 4-bromobenzaldehyde and pyrrolidine by the same method (step B) described in Example 1.

Step B

The mixture of 4-bromobenzyl-pyrrolidine (1 equiv, 240 mg), $\text{Pd}_2(\text{dba})_3$ (2.0% equiv, 18.3 mg), $t\text{-Bu}_3\text{P}$ (1.6% equiv, 3.2 mg), benzylamine (0.5 equiv, 53.6 mg) and $\text{NaO}t\text{Bu}_3$ (1.5 equiv, 144 mg) in toluene (5 mL) was heated at 70°C for 8 h. Concentration and preparative TLC provided the title compound (80 mg). ^1H NMR (400 MHz, CDCl_3) δ 7.26 (m, 9H), 7.00 (d, $J = 8.6$ Hz, 4H), 4.97 (s, 2H), 3.68 (s, 4H), 3.60 (s, 2H), 2.68 (m, 8H), 1.86 (m, 4H).

20

Example 24



(3-Piperidin-1-yl-propyl)-bis-(4-pyrrolidin-1-ylmethyl-phenyl)-amine


 $K_i = 3.5 \text{ nM}$

5

The title compound was prepared starting from 4-bromobenzyl-pyrrolidine and 3-piperidin-1-yl-propyl amine by the same method (step B) described in example 23. ¹H NMR (400 MHz, CDCl₃) δ 7.26 (d, J = 8.6 Hz, 4H), 7.00 (d, J = 8.6 Hz, 4H), 3.74 (t, J = 7.3, 2H), 3.64 (s, 4H), 2.60 (m, 8H), 2.36 (m, 6H), 1.85 (m, 10 H), 1.64 (m, 4H), 1.46 (m, 2H).

10

Example 25



(2-(N,N-dimethylamine)ethyl)-bis-(4-pyrrolidin-1-ylmethyl-phenyl)-amine


15 N,N-Dimethyl-N',N'-bis-(4-pyrrolidin-1-ylmethyl-phenyl)-ethane-1,2-d

Ki = 453 nM

The title compound was prepared starting from 4-bromobenzyl-pyrrolidine and 2-(N,N-dimethylamine)ethylamine by the same method (step B) described in example 23. ¹H NMR (400 MHz, CDCl₃) δ 7.26 (m, 4H), 6.96 (m, 4H), 3.85 (t, J = 7.9 Hz, 2H), 3.60 (s, 4H), 2.60 (m, 10H), 2.29 (s, 6H), 1.83 (m, 8 H).

20


Example 26



25 1-[4-(4-Piperidine-phenylsulfanyl)-3-nitro-benzyl]-piperidine

Ki = 756 nM

5




Step A 1-[4-(3-Bromo-phenylsulfanyl)-3-nitro-benzyl]-piperidine

A solution of 4-(4-Bromo-phenylsulfanyl)-3-nitro-benzaldehyde (338 mg), piperidine (98.9 μ L), and acetic acid (0.12 mL) in DCM (10 mL) was treated with sodium triacetoxyborohydride (274 mg). After 5 hours, the resulting mixture was evaporated. The product was used in the next step without purification.

Step B 1-[4-(4-Piperidine-phenylsulfanyl)-3-nitro-benzyl]-piperidine

A solution of the product in step A (133 mg), sodium tert-butoxide (48mg), tris(dibenzylideneacetone)dipalladium(0) (5.95mg), tri-tert-butylphosphine (13 μ L), and piperidine (0.33 mL) in dioxane (2 mL) was stirred at 90 °C for 16 hours. Next day, another equivalent of piperidine (0.33 mL) was added, and the reaction was stirred at 90 °C for 2 days and then concentrated. The residue was purified via preparative thin layer chromatography eluting with 1:1 DCM:EtOAc to give the title compound (35.3 mg). 1 H NMR (400 MHz, CDCl_3) δ 8.15 (d, J = 1.8, 1H), 7.40 (d, J = 8.9, 2H), 7.29 (dd, J = 8.4, 1.9, 1H), 6.96 (d, J = 8.9, 2H), 6.80 (d, J = 8.4, 1H), 3.42 (s, 2H), 3.28 (m, 4H), 2.34 (br, 4H), 1.73 (m, 4H), 1.62 (m, 2H), 1.53 (m, 2H), 1.42 (m, 2H). 13 C NMR (400 MHz, CDCl_3) δ 152.8, 144.3, 139.6, 137.3, 136.2, 134.0, 127.8, 125.8, 117.6, 116.5, 76.7, 62.2, 54.4, 49.3, 25.9, 25.5, 24.24, 24.22.

25 Example 27




4'-Pyrrolidin-1-ylmethyl-biphenyl-4-carbaldehyde

5 $K_i = 8.7 \text{ nM}$

A solution of biphenyl-4,4'-dicarbaldehyde (0.21 g), pyrrolidine (83 μL), and acetic acid (57 μL) in DCM (5 mL) was treated with sodium triacetoxyborohydride (0.34 g). After 16 hours, the resulting mixture was treated with 3M NaOH (1.5 mL) 10 and extracted with DCM (3 x 10 mL). The combined organic phases were dried over sodium sulfate and evaporated. The residue was purified via preparative thin layer chromatography eluting with 5% MeOH/DCM to give the title compound (42.5 mg).
15 ^1H NMR (400 MHz, CDCl_3) δ 10.05 (s, 1H), 7.94 (d, $J = 8.0$, 2H), 7.75 (d, $J = 8.0$, 2H), 7.60 (d, $J = 8.0$, 2H), 7.47 (d, $J = 8.0$, 2H), 3.72 (s, 2H), 2.61 (br s, 4H), 1.84 (br s, 4H).

Example 28




4'-Pyrrolidin-1-ylmethyl-biphenyl-4-carbaldehyde oxime

20 $K_i = 6.5 \text{ nM}$

A solution of Example 27 (33.7 mg), sodium carbonate (27.6 mg), and hydroxylamine hydrochloride (18 mg) in ethanol (5 mL) was set to reflux for 16 hours. Inorganic solid was filtered out and washed with DCM and acetone. Organic 25 layer was concentrated under reduced pressure to give the titled compound (12 mg) without purification. ^1H NMR (400 MHz, CDCl_3) δ 8.19 (s, 1H), 7.82-7.69 (m, 8H), 4.37 (d, $J = 6.3$, 2H), 3.35 (m, 2H), 3.10-3.03 (m, 2H), 2.06-1.94 (m, 2H), 1.93-1.88 (m, 2H).

30 Example 29


5



1-(2-{4-[2-(1-phenethyl-pyrrolidine)-ethyl]-phenyl}-ethyl)-pyrrolidine


 $K_i = 26.6 \text{ nM}$

10



Step A 2-(4-{2-[4-(2-Hydroxy-ethyl)-phenyl]-ethyl}-phenyl)-ethanol

A solution of {4-[2-(4-ethoxycarbonylmethyl-phenyl)-ethyl]-phenyl}-acetic acid ethyl ester (0.207 g) in THF (8 mL) was protected with N_2 and treated with $LiAlH_4$ (0.039 g) and stirred at rt. $LiAlH_4$ was added until the reaction went to completion. It was then quenched with H_2O (0.1 mL), 10% NaOH (0.15 mL), and H_2O (0.3 mL), and filtered through celite. The filtrate was concentrated to yield the titled compound (0.101 g) and was used without further purification.




Step B 1-{2-[(2-Chloro-ethyl)-benzene]-ethyl}-4-(2-chloro-ethyl)-benzene

A solution of the product of Step A in DCM (7 mL) was treated with thionyl chloride at 30 °C for 3 days. Solvent was removed in vacuo to give the titled compound, which was used without purification.

Step C 1-(2-{4-[2-(1-Phenethyl-pyrrolidine)-ethyl]-phenyl}-ethyl)-pyrrolidine

5 A solution of the product of Step B in acetonitrile (10 mL) was treated with pyrrolidine (76 μ L), potassium carbonate (0.174 g) and tetra-N-butylammonium iodide (5 mg). The reaction was heated at reflux until completion. Solvent was removed via *vacuo* and the residue was dissolved in DCM and washed with bicarbonate. The organic layer was dried over sodium sulfate, filtered and
 10 concentrated. Purification via preparative thin layer chromatography eluting with 5% MeOH/DCM to give the title compound (6.8 mg). 1 H NMR (400, CDCl_3) δ 7.15 – 7.12 (m, 8H), 2.89 – 2.85 (m, 8H), 2.79 – 2.66 (m, 4H), 2.57 (m, 8H), 1.81 (m, 8H).


Example 30



15


3-Pyrrolidin-1-ylmethyl-1-(4-pyrrolidin-1-ylmethyl-benzyl)-1H-pyrrole

$K_i = 24.2 \text{ nM}$




20 Step A Pyrrole-3-carbaldehyde

A solution of pyrrole-2-carbaldehyde (3 g) in DCE (30 mL) was treated with triflic acid and stirred at reflux for 16 hours. The reaction was cooled to rt and poured into ether (30 mL) and neutralized with potassium carbonate (47 g) and NaOH (13.6 g) in H_2O (20 mL). Organic layer was dried over sodium sulfate and
 25 concentrated. The residue was purified via silica gel chromatography eluting with 1:1 Ether/Hexanes to give the title compound (0.42 g).




5 Step B 4-Pyrrolidin-1-ylmethyl-benzoic acid methyl ester
 A solution of 4-formyl-benzoic acid methyl ester (10 g), pyrrolidine (5.6 mL),
 and acetic acid (3.5 mL) in DCM (200 mL) was treated with sodium
 triacetoxyborohydride (20.65 g) and stirred at rt for 16 hours. The reaction mixture
 was then quenched with 3N NaOH (70 mL). The organic layer was dried over
 10 sodium sulfate and concentrated to yield the titled compound without purification.




Step C (4-Pyrrolidin-1-ylmethyl-phenyl)-methanol

A solution of the product in step B (0.207 g) in THF (8 mL) was protected with
 N₂ and treated with LiAlH₄ (0.039 g) and stirred at rt. LiAlH₄ was added until the
 15 reaction went to completion. It was quenched with H₂O (0.1 mL), 10% NaOH (0.15
 mL), and H₂O (0.3 mL), then filtered through celite. The filtrate was concentrated to
 yield the titled compound (0.101 g) and was used without further purification.



Step D 1-(4-Chloromethyl-benzyl)-pyrrolidine

20 A solution of the product of Step C in DCM (200 mL) was treated with thionyl
 chloride (20 mL) at 40 °C for 16 hours. Solvent was removed in vacuo to give the
 titled compound (15 g), which was used without purification.



Step E 1-(4-Pyrrolidin-1-ylmethyl-benzyl)-1H-pyrrole-3 carbaldehyde

25 A solution of the product in Step A (0.2 g) and Step D (0.51 g) in benzene (2
 mL) was treated with 50% NaOH (2 mL), tetrabutylammonium hydrogen sulfate (84
 mg) and stirred at 80 °C for 3 hours. The mixture was cooled to room temperature
 and diluted in water (10 mL) and extracted with ether (3 x 10 mL). The organic layer


5 was dried over magnesium sulfate, filtered and concentrated to yield the titled compound (0.45 g) without purification.

Step F 3-Pyrrolidin-1-ylmethyl-1-(4-pyrrolidin-1-ylmethyl-benzyl)-1H-pyrrole

A solution of the produce from step E (0.45 g), pyrrolidine (156 μ L), and acetic acid (97 μ L) in DCM (6 mL) was treated with sodium triacetoxyborohydride


10 (576 mg) and stirred at rt for 16 hours. The reaction mixture was then quenched with 3N NaOH (3 mL). The organic layer was dried over sodium sulfate and concentrated. The residue was purified via silica gel chromatography eluting with 0-5% MeOH/DCM to give the title compound (44.7 mg) as yellow oil. 1 H NMR (400 MHz, CDCl_3) δ 7.26 (d, J = 7.9, 2H), 7.04 (d, J = 7.9, 2H), 6.69 (s, 1H), 6.59 (s, 1H), 15 6.15 (s, 1H), 4.98 (s, 2H), 3.65 (s, 2H), 3.58 (s, 2H), 2.72 (br m, 4H), 2.48 (br m, 4H).

Example 31



2-Pyrrolidin-1-ylmethyl-1-(4-pyrrolidin-1-ylmethyl-benzyl)-1H-pyrrole

20 K_i = 3.2 nM



Step A 1-(4-Pyrrolidin-1-ylmethyl-benzyl)-1H-pyrrole-2-carbaldehyde

A solution of product from step D example 31 (5.2 g) and pyrrole-2-

25 carboxaldehyde (2.0 g) in benzene (20 mL) was treated with 50% NaOH (20 mL), tetrabutylammonium hydrogen sulfate (0.8 g) and stirred at 80 °C for 3 hours. The mixture was cooled to rt and diluted in water (40 mL) and extracted with ether (3 x


5 40 mL). The organic layer was dried over magnesium sulfate, filtered and concentrated to yield the titled compound (5.2 g) without purification.

Step B 2-Pyrrolidin-1-ylmethyl-1-(4-pyrrolidin-1-ylmethyl-benzyl)-1H-pyrrole

A solution of the produce from step A (0.46 g), pyrrolidine (156 μ L), and acetic acid (97 μ L) in DCM (6 mL) was treated with sodium triacetoxyborohydride

10 (0.57 g) and stirred at rt for 16 hours. The reaction mixture was then quenched with 3N NaOH (3 mL). The organic layer was dried over sodium sulfate and concentrated. The residue was purified via silica gel chromatography eluting with 0-5% MeOH/DCM to give the title compound (0.27 g) as dark orange oil. 1 H NMR (400 MHz, CDCl_3) δ 7.26 (d, J = 7.8, 2H), 7.00 (d, J = 7.8, 2H), 6.62 (s, 1H), 6.08-6.07 (m, 1H), 6.03 (s, 1H), 5.19 (s, 2H), 3.57 (s, 2H), 3.45 (s, 2H), 2.48 (m, 4H), 2.42 (m, 4H), 1.77 (m, 4H), 1.71 (m, 4H).

Example 32




Bis-[4-(3-dimethylamino-propylsulfanyl)-phenyl]-methanone dihydrochloride

K_i = 14 nM

To NaH (1.59 g, 60% suspension in mineral oil) was added at room temperature *n*-butanol (80 mL) followed by 3-dimethylamino-propane-1-thiol hydrochloride (3.65, 85 %), bis-(4-chloro-phenyl)-methanone (5.00 g), and $\text{Pd}(\text{PPh}_3)_4$ (4.62 g). The reaction mixture was heated under reflux for 6 h and was allowed to cool down to room temperature. Ether (500 mL) was added and the organic layer was washed with water (3x100 mL). The organic layer was extracted with HCl (1N in water, 3x150 mL) and the combined aqueous layers were washed with ether (3x200

5 mL) and were brought to pH = 13 with NaOH (1N in water). The aqueous layers was extracted with ether (3x200 mL) and the combined organic layers were washed with water (150 mL) and brine (150 mL). The organic layers were dried over magnesium sulfate and the solvent was removed in vacuo. The crude product was separated and purified by flash chromatography on silica gel (chloroform/methanol) to give the 10 title compound as a colorless solid (280 mg). ^1H NMR (400 MHz, CDCl_3): 7.72 (d, 4H), 7.37 (d, 4H), 3.08 (t, 4H), 2.43 (t, 4H), 2.25 (s, 12H), 1.84-1.93 (m, 4H).

Example 33




[4-(3-Dimethylamino-propoxy)-phenyl]-[4-hydroxy-phenyl]-methanone

K_i = 129 nM

20 To a stirred solution of bis-(4-hydroxy-phenyl)-methanone (7.00 g) in methanol (130 mL) was added at room temperature $t\text{-Bu}_3\text{OK}$ (14.7 g) followed by (3-chloro-propyl)-dimethyl-amine (10.3 g). The reaction mixture was heated under reflux for 18 h and was allowed to cool down to room temperature. Water (50 mL) was added and the solvent was removed in vacuo. Methylene chloride (650 mL) was 25 added and the organic layer was washed with water (2x150 mL). The organic layer was dried over magnesium sulfate and the solvent was removed in vacuo. The crude products were separated and purified by flash chromatography on silica gel (chloroform/2 M ammonia in methanol) to give the title compound bis-[4-(3-dimethylamino-propoxy)-phenyl]-methanone as a colorless residue (250 mg). ^1H NMR (400 MHz, CD_3OD): 7.78 (d, 4H), 7.09 (d, 4H), 4.22 (t, 4H), 3.37-3.40 (m, 4H), 30

5 2.96 (s, 12H), 2.24-2.31 (m, 4H). And title compound [4-(3-dimethylamino-propoxy)-phenyl]-[4-hydroxy-phenyl]-methanone as a colorless residue (150 mg). ^1H NMR (400 MHz, CD_3OD): 7.88-7.99 (m, 4H), 7.25-7.29 (m, 2H), 7.08-7.13 (m, 2H), 4.48 (t, 2H), 2.69-2.76 (m, 2H), 2.56 (s, 6H), 2.23-2.30 (m, 2H).

10 Example 34



Bis-[4-(2-dimethylamino-ethoxy)-phenyl]-methanone

$K_i = 126 \text{ nM}$

15

To a stirred solution of bis-(4-hydroxy-phenyl)-methanone (10.0 g) in ethanol (40.0 mL) was added at room temperature $t\text{-Bu}_3\text{OK}$ (6.73 g) followed by (3-chloroethyl)-dimethyl-amine (5.76 g). The reaction mixture was heated under reflux for 24
20 h and was allowed to cool down to room temperature. Methylene chloride (500 mL) was added and the organic layer was washed with water (3x75 mL). The organic layer was dried over magnesium sulfate and the solvent was removed in vacuo. The crude products were separated and purified by flash chromatography on silica gel (chloroform/2 M ammonia in methanol) to give the title compound as pale brown
25 crystals (370 mg). ^1H NMR (400 MHz, CDCl_3): 7.78 (d, 4H), 6.98 (d, 4H), 4.16 (t, 4H), 2.80 (t, 4H), 2.38 (s, 12 H).

5 Example 35

BIOLOGICAL METHODSIn Vitro

10 Transfection of cells with human histamine receptor

A 10 cm tissue culture dish with a confluent monolayer of SK-N-MC cells was split two days prior to transfection. Using sterile technique the media was removed and the cells were detached from the dish by the addition of trypsin. One fifth of the cells were then placed onto a new 10 cm dish. Cells were grown in a 37°C

15 incubator with 5% CO₂ in Minimal Essential Media Eagle with 10% Fetal Bovine Serum. After two days cells were approximately 80% confluent. These were removed from the dish with trypsin and pelleted in a clinical centrifuge. The pellet was then re-suspended in 400 µL complete media and transferred to an electroporation cuvette with a 0.4 cm gap between the electrodes (Bio-Rad #165-20 2088). One microgram of supercoiled H₃ receptor cDNA was added to the cells and mixed. The voltage for the electroporation was set at 0.25 kV; the capacitance was set at 960 µF. After electroporation the cells were diluted into 10 mL complete media and plated onto four 10 cm dishes. Because of the variability in the efficiency of electroporation, four different concentrations of cells were plated. The ratios used

25 were; 1:20, 1:10, 1:5, with the remainder of the cells being added to the fourth dish. The cells were allowed to recover for 24 hours before adding the selection media (complete media with 600 µg/mL G418). After 10 days dishes were analyzed for surviving colonies of cells. Dishes with well isolated colonies were used. Cells from individual colonies were isolated and tested. SK-N-MC cells were used because they

30 give efficient coupling for inhibition of adenylate cyclase. The clones that gave the most robust inhibition of adenylate cyclase in response to histamine were used for further study.

5

[³H]-N-methylhistamine binding

Cell pellets from histamine H₃ receptor-expressing SK-N-MC cells were homogenized in 20 mM TrisHCl/0.5 mM EDTA. Supernatants from a 800 g spin were collected, re-centrifuged at 30,000 g for 30 minutes. Pellets were re-

10 homogenized in 50 mM Tris/5 mM EDTA (pH 7.4). Membranes were incubated with 0.8 nM [³H]-N-methylhistamine plus/minus test compounds for 45 min at 25°C and harvested by rapid filtration over GF/C glass fiber filters (pretreated with 0.3 % polyethylenimine) followed by four washes with ice cold buffer. Filters were dried, added to 4 mL scintillation cocktail and then counted on a liquid scintillation counter.

15 Non-specific binding was defined with 10 μ M histamine. The pK_i values were calculated based on a K_d of 800 pM and a ligand concentration ([L]) of 800 pM according to the formula:

$$K_i = (IC_{50}) / (1 + ([L] / (K_d)))$$

20

In Vivo

Elucidation of oral absorption and blood-brain barrier penetration profiles of H₃ receptor antagonists in the rat

25 A rat *in vivo* system was used to determine the blood-brain barrier penetration profiles and kinetics of various H₃ receptor antagonists after single bolus oral administration.

Female Sprague Dawley Rats (~300 gram body weight) were housed in accordance with institutional standards and allowed to acclimate for at least 7 days prior to the study. Each H₃ antagonist was formulated in 0.5% hydroxypropylmethyl 30 cellulose at a concentration of 1 mg/mL for oral dosing. The test compound was administered to each of eight animals as a single oral dose of 10 mL/kg (10 mg/kg). Remaining dosing solution was retained for analysis. Two animals from each original group of eight were euthanized via CO₂ asphyxiation at t = 1, 6, 24, and 48

5 hours. After each animal was euthanized, 0.1 mL of its blood was sampled via cardiac puncture, and its brain was removed via dissection of the cranial bones and placed in a pre-weighed 50 mL conical tube on dry ice.

The blood was added to 0.3 mL of 6% trichloroacetic acid, and the acidified sample was vortexed and then centrifuged (5 minutes at 14,000 rpm in a 10 microcentrifuge). The clear supernatant was retained for analysis. The frozen brain was weighed, homogenized in 6% trichloroacetic acid (3 mL/g wet weight of tissue), and then centrifuged. The clear supernatant was retained for analysis. The supernatants from the blood and brain samples were analyzed by liquid chromatography with mass spectral detection utilizing selective reaction monitoring 15 (LC-MS/MS). The LC method used a Phenomenex Polar RP column (2 x 50 mm) and a linear solvent gradient of water and acetonitrile (both 1% in acetic acid).

Graphs of H_3 receptor antagonist concentration versus time for blood and brain were generated from the LC-MS/MS results. The mean residency time (MRT) of the H_3 receptor antagonist, in blood or in the brain, was calculated from the ratio 20 of the area under the first moment curve (AUMC) to the area under the concentration time curve (AUC): $AUMC/AUC$. The Blood Brain Barrier index was calculated from the log of $AUC_{\text{brain}}/AUC_{\text{blood}}$.

F. Other Embodiments

25

The features and advantages of the invention will be apparent to one of ordinary skill in view of the discussion, examples, embodiments, and claims relating to the invention. The invention also contemplates variations and adaptations, based on the disclosure herein concerning the key features and advantages of the 30 invention, and within the abilities of one of ordinary skill.


What is claimed is:

5

CLAIMS

1. A compound of formula (I):

10



(I)

wherein each of W₁ and W₂ is H;

15

X₁ is selected from G_a, R_aG_a, L_aG_a, and R_aL_aG_a;X₂ is selected from G_b, R_bG_b, L_bG_b, and R_bL_bG_b;

20

each of G_a and G_b is independently NR_{3a}R_{4a} or NR_{3b}R_{4b}, respectively, orpyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, isoindolinyl, morpholinyl, piperazinyl, imidazolyl, thiazolinyl, 5,6-dihydro-3-imidazo[2,1-B]thiazolyl, or thiazolyl; wherein each of R_{3a}, R_{4a}, R_{3b} and R_{4b} is independently selected from H, C₁₋₈ alkyl, C₃₋₇ cycloalkyl, and (C₃₋₇ cycloalkyl)C₁₋₆ alkyl;

25

G_b can be further selected from nitro, halo, OH, CHO, pyrrolyl, or -C(=NOH)H;each of R_a and R_b is independently O, S, NH or C=O;

5 each of L_a and L_b is independently C_{1-3} alkylene;

Y is a covalent bond where one of Z_1 and Z_2 is N, O, or S; Y can also be SO_2 , $C=O$, CH_2 , CH_2CH_2 , OCH_2 , CH_2O , or NR_c , wherein R_c is H, C_{1-8} alkyl, C_{3-7} cycloalkyl, $(C_{3-7}$ cycloalkyl) C_{1-6} alkyl, C_{2-5} heterocyclyl, $(C_{2-7}$ heterocyclyl) C_{1-6} alkyl, phenyl, (phenyl) C_{1-6} alkyl, or [di (C_{1-6} alkyl)amino] C_{1-6} alkyl;

each of Z_1 and Z_2 is independently N, O, S, or $-CH=CH-$ to form a phenyl ring;

15 or a pharmaceutically acceptable salt, amide or ester thereof.

2. A compound of claim 1, wherein each of G_a and G_b is independently $NR_{3a}R_{4a}$ or $NR_{3b}R_{4b}$, respectively, or pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, isoindolinyl, morpholinyl, piperazinyl, imidazolyl, thiazolinyl, 5,6-dihydro-3-imidazo[2,1-B]thiazolyl, or thiazolyl; wherein each of R_{3a} , R_{4a} , R_{3b} and R_{4b} is independently selected from H, C_{1-8} alkyl, C_{3-7} cycloalkyl, and $(C_{3-7}$ cycloalkyl) C_{1-6} alkyl;

25 3. A compound of claim 1, wherein X_1 is L_aG_a .

4. A compound of claim 1, wherein X_2 is L_bG_b .

5. A compound of claim 1, wherein X_1 is L_aG_a and X_2 is L_bG_b .

30 6. A compound of claim 1, wherein X_1 and X_2 are independently selected from pyrrolidinylmethyl, piperidylmethyl, di(C_{1-2} alkyl)amino (C_{2-5} alkyl), and di(C_{1-2} alkyl)amino(C_{2-5} alkoxy).

5 7. A compound of claim 1, wherein X_1 is selected from G_a , R_aG_a , or
 $R_aL_aG_a$.

10 8. A compound of claim 1, wherein X_2 is selected from G_b , R_bG_b , or
 $R_bL_bG_b$.

15 9. A compound of claim 1 wherein X_1 and X_2 are the same.

20 10. A compound of claim 1, wherein each of G_a and G_b is independently
 NR_3R_4 , pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, isoindolinyl,
morpholinyl, thiazolyl, thiazolinyl, 5,6-dihydro-3-imidazo[2,1-B]thiazolyl,
or piperazinyl; where R_3 and R_4 are each independently selected from
H and C_{1-4} alkyl.

25 11. A compound of claim 1, wherein Y is O, S, SO_2 , $C=O$, CH_2 , OCH_2 ,
 CH_2O , or NR_c , wherein R_c is H, C_{1-8} alkyl, C_{3-7} cycloalkyl, $(C_{3-7}$
cycloalkyl) C_{1-6} alkyl, C_{2-5} heterocyclyl, $(C_{2-7}$ heterocyclyl) C_{1-6} alkyl,
phenyl, (phenyl) C_{1-4} alkyl, or [di (C_{1-4} alkyl)amino] C_{1-6} alkyl.

30 12. A compound of claim 1, selected from the group consisting of:
1-[(4-(4-Pyrrolidin-1-ylmethyl-phenyl)-thiophen)-2-ylmethyl]-pyrrolidine;
1-[(4-(4-Pyrrolidin-1-ylmethyl-phenyl)-furan)-2-ylmethyl]-pyrrolidine;
1-((4-(4-Pyrrolidin-1-ylmethyl-thiophen)-2-ylthiophen)-2-ylmethyl)-pyrrolidine;
1-[(2-(4-Pyrrolidin-1-ylmethyl-phenyl)-thiophen)-3-ylmethyl]-pyrrolidine;
1-[(3-(4-Pyrrolidin-1-ylmethyl-phenyl)-thiophen)-2-ylmethyl]-pyrrolidine;
1-((4-(4-Pyrrolidin-1-ylmethyl-pyridin)-2-ylpyridin)-2-ylmethyl)-pyrrolidine;
1-[4-(3,5-Dichloro-phenoxy)-benzyl]-pyrrolidine;
1-[4-(4-Piperidine-phenylsulfanyl)-3-nitro-benzyl]-piperidine;
4'-Pyrrolidin-1-ylmethyl-biphenyl-4-carbaldehyde;

5 4'-Pyrrolidin-1-ylmethyl-biphenyl-4-carbaldehyde oxime;
3-Pyrrolidin-1-ylmethyl-1-(4-pyrrolidin-1-ylmethyl-benzyl)-1*H*-pyrrole; and
2-Pyrrolidin-1-ylmethyl-1-(4-pyrrolidin-1-ylmethyl-benzyl)-1*H*-pyrrole.

13. A compound of claim 1, selected from the group consisting of:
10 1-[4-(4-Pyrrolidin-1-ylmethyl-phenoxy)-benzyl]-pyrrolidine;
1-[4-(4-Piperidin-1-ylmethyl-phenoxy)-benzyl]-piperidine;
1-[4-(4-Pyrrolidin-1-ylmethyl-benzenesulfonyl)-benzyl]-pyrrolidine;
1-[4-(4-Pyrrolidin-1-ylmethyl-benzyl)-benzyl]-pyrrolidine;
15 1-[4-(4-Imidazo-1-ylmethyl-phenoxy)-benzyl]-imidazole;
1-[4-(4-Imidazo-1-ylmethyl-benzyl)-benzyl]-imidazole;
[4-(N, N'-dimethyl-isothiourea)-methyl-phenoxy]-benzyl]-N, N'-dimethyl-
isothiourea;
[4-(N-methyl-isothiourea)-methyl-phenoxy]-benzyl]-N-methyl-isothiourea;
20 2-[4-(4-(2-Imidazolidin)-2-ylthiomethyl-phenoxy)-benzyl-thio]-2-imidazolidine;
2-[4-(4-(2-Thiazolin)-2-ylthiomethyl-phenoxy)-benzyl-thio]-2-thiazoline;
2-[4-(4-(1-Methyl-imidazo)-2-ylthiomethyl-phenoxy)-benzyl-thio]-1-methyl-
imidazole;
25 2-[4-(4-(2-Imidazolidin)-2-ylaminomethyl-phenoxy)-benzyl-amino]-2-
imidazolidine; and
1-(2-{4-[2-(1-phenethyl-pyrrolidine)-ethyl]-phenyl}-ethyl)-pyrrolidine.

14. A compound of claim 1, selected from the group consisting of:
1-[4-(4-Bromo-benzyloxy)-benzyl]-pyrrolidine;
1-[4-(4-Pyrrolidin-1-ylmethyl-phenoxy)methyl]-benzyl]-1*H*-pyrrole; and
30 1-(4-Pyrrolidin-1-ylmethyl-benzyl)-1*H*-pyrrole.

15. A compound of claim 1, selected from the group consisting of:
Benzyl-(4-pyrrolidin-1-ylmethyl-phenyl)-amine;

5 Benzyl-bis-(4-pyrrolidin-1-ylmethyl-phenyl)-amine;
 (3-Piperidin-1-yl-propyl)-bis-(4-pyrrolidin-1-ylmethyl-phenyl)-amine
 ; and
 (2-(N,N-dimethylamine)ethyl)-bis-(4-pyrrolidin-1-ylmethyl-phenyl)-amine.

10 16. The compound of claim 1, 3-[4-(4-(5,6-Dihydro-3-imidazo[2,1-B]thiazol)-3-ylphenoxy)-phenyl]-(5,6-dihydro-3-imidazo[2,1-B]thiazole).

15 17. A compound of claim 1, selected from the group consisting of:
 Bis-[4-(3-dimethylamino-propylsulfanyl)-phenyl]-methanone dihydrochloride;
 Bis-[4-(3-dimethylamino-propoxy)-phenyl]-methanone;
 [4-(3-Dimethylamino-propoxy)-phenyl]-(4-hydroxy-phenyl)-methanone;
 Bis-[4-(2-dimethylamino-ethoxy)-phenyl]-methanone;

20 18. A pharmaceutical composition, comprising a compound of claim 1 and
 a pharmaceutically acceptable carrier.

25 20. A compound of claim 1, isotopically labelled to be detectable by PET or
 SPECT.

30 21. A method of inhibiting histamine H₃ receptor activity in a subject,
 comprising administering an effective amount of a compound of claim
 1 to a subject in need of such inhibition of histamine H₃ receptor
 activity.

22. A method of treating a subject having a disease or condition
 modulated by histamine H₃ receptor activity, comprising administering
 to the subject a therapeutically effective amount of a compound of
 claim 1.]

5

23. A method of claim 22, wherein said disease or condition is selected from the group consisting of sleep/wake disorders, arousal/vigilance disorders, migraine, asthma, dementia, mild cognitive impairment (pre-dementia), Alzheimer's disease, epilepsy, narcolepsy, eating disorders, motion sickness, vertigo, attention deficit hyperactivity disorders, learning disorders, memory retention disorders, schizophrenia, nasal congestion, allergic rhinitis, and upper airway allergic response.

10

24. A method for treating a disease or condition modulated by at least one receptor selected from the histamine H₁ receptor and the histamine H₃ receptor, said method comprising (a) administering to a subject a jointly effective amount of a histamine H₁ receptor antagonist compound, and (b) administering to the subject a jointly effective amount of a compound of claim 1, said method providing a jointly therapeutically effective amount of said compounds.

15

25. The method of claim 24 wherein the histamine H₁ receptor antagonist and the compound of claim 1 are present in the same dosage form.

20

26. A method for treating diseases or conditions modulated by at least one receptor selected from the histamine H₂ receptor and the histamine H₃ receptor in a subject, comprising (a) administering to the subject a jointly effective amount of a histamine H₂ receptor antagonist compound, and (b) administering to the subject a jointly effective amount of a compound of claim 1, said method providing a jointly therapeutically effective amount of said compounds.

25

30

5 27. The method of claim 26 wherein the histamine H₂ receptor antagonist and the compound of claim 1 are present in the same dosage form.

10 28. A method for treating one or more disorders or conditions selected from the group consisting of sleep/wake disorders, narcolepsy, and arousal/vigilance disorders, comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

15 29. A method for treating attention deficit hyperactivity disorders (ADHD), comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

20 30. A method for treating one or more disorders or conditions selected from the group consisting of dementia, mild cognitive impairment (pre-dementia), cognitive dysfunction, schizophrenia, depression, manic disorders, bipolar disorders, and learning and memory disorders, comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

25 31. A method for treating or preventing upper airway allergic response, nasal congestion, or allergic rhinitis, comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

30 32. A method for studying disorders mediated by the histamine H₃ receptor, comprising using an ¹⁸F-labeled compound of claim 1 as a positron emission tomography (PET) molecular probe.

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number
WO 02/012224 A3(51) International Patent Classification⁷: C07D 333/20, 307/52, 295/096, 295/135, 233/60, 233/58, C07C 335/32, C07D 233/84, 277/36, 233/88, 207/325, 295/112, 207/335, C07C 323/32, 225/16, A61K 31/381, 31/341, 31/40, 31/4453, 31/4164, A61P 25/00, 9/00, C07D 233/42

(74) Agents: JOHNSON, Philip, S. et al.; One Johnson & Johnson Plaza, New Brunswick, NJ 08903 (US).

(21) International Application Number: PCT/US01/24654

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 6 August 2001 (06.08.2001)

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

(30) Priority Data:

60/223,768 8 August 2000 (08.08.2000) US
09/922,622 6 August 2001 (06.08.2001) US

Published:

— with international search report

(71) Applicant: ORTHO MCNEIL PHARMACEUTICAL, INC. [US/US]; U.S. Route 202, P.O. Box 300, Raritan, NJ 08869-0602 (US).

(88) Date of publication of the international search report: 18 July 2002

(72) Inventors: BOGENSTAETTER, Michael; 239 24th Street, Del Mar, CA 92014 (US). CHAI, Wenyi; 9519 Compass Point Drive South, San Diego, CA 92126 (US). KWOK, Annette, K.; 10770 Aderman Avenue, #92, San Diego, CA 92126 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/012224 A3

(54) Title: BICYCLIC COMPOUNDS AS H3 RECEPTOR LIGANDS

(57) Abstract: Substituted N-substituted alkoxyphenyl compounds, compositions containing them, and methods of making and using them.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/24654

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C07D333/20	C07D307/52	C07D295/096	C07D295/135	C07D233/60
	C07D233/58	C07C335/32	C07D233/84	C07D277/36	C07D233/88
	C07D207/325	C07D295/112	C07D207/335	C07C323/32	C07C225/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication where appropriate of the relevant passages	Relevant to claim No
A	WO 99 42458 A (JAMES BLACK FOUNDATION LIMITED) 26 August 1999 (1999-08-26) cited in the application the whole document ---	1-32
A	WO 97 17345 A (SYNTHELABO) 15 May 1997 (1997-05-15) the whole document ---	1-32
A	WO 95 14007 A (SCHERING CORPORATION) 26 May 1995 (1995-05-26) the whole document ---	1-32
A	WO 93 20061 A (THE UNIVERSITY OF TOLEDO) 14 October 1993 (1993-10-14) the whole document ---	1-32
		-/-

Further documents are listed in the continuation of box C

Patent family members are listed in annex

* Special categories of cited documents

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

& document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

10 April 2002

18/04/2002

Name and mailing address of the ISA

European Patent Office, P B 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx 31 651 epo nl.
Fax (+31-70) 340-3016

Authorized officer

Kyriakakou, G

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/US 01/24654

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/381 A61K31/341 A61K31/40 A61K31/4453 A61K31/4164
A61P25/00 A61P9/00 C07D233/42

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HOLGER STARK ET AL.: "Developments of histamine H3-antagonists" DRUGS OF THE FUTURE, vol. 21, no. 5, 1996, pages 507-520, XP002084872 BARCELONA, ES ISSN: 0377-8282 cited in the application the whole document ---	1-32
A	RONALD WOLIN ET AL.: "Novel H3 receptor antagonists. Sulfonamide Homologs of Histamine" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, no. 8, 1998, pages 2157-2162, XP004137238 OXFORD, GB ISSN: 0960-894X the whole document -----	1-32

Further documents are listed in the continuation of box C

Patent family members are listed in annex

* Special categories of cited documents

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

10 April 2002

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040. Tx 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Kyriakakou, G

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Application No

PCT/US 01/24654

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9942458	A 26-08-1999	AU 2535499 A		06-09-1999
		BR 9908074 A		24-10-2000
		CA 2318836 A1		26-08-1999
		CN 1296478 T		23-05-2001
		EP 1056733 A1		06-12-2000
		WO 9942458 A1		26-08-1999
		JP 2002504483 T		12-02-2002
		NO 20003918 A		03-10-2000
		ZA 9901356 A		21-08-2000
WO 9717345	A 15-05-1997	FR 2741069 A1		16-05-1997
		FR 2741070 A1		16-05-1997
		FR 2745574 A1		05-09-1997
		AT 181328 T		15-07-1999
		AU 707325 B2		08-07-1999
		AU 7500196 A		29-05-1997
		BG 63463 B1		28-02-2002
		BG 102412 A		31-08-1999
		BR 9611311 A		29-06-1999
		CA 2236357 A1		15-05-1997
		CN 1202169 A , B		16-12-1998
		CZ 9801421 A3		12-08-1998
		DE 69602970 D1		22-07-1999
		DE 69602970 T2		20-01-2000
		EE 9800155 A		15-12-1998
		EP 0863897 A1		16-09-1998
		ES 2135934 T3		01-11-1999
		WO 9717345 A1		15-05-1997
		GR 3030823 T3		30-11-1999
		HK 1016165 A1		22-09-2000
		HU 0001168 A2		28-04-2001
		JP 2000500125 T		11-01-2000
		NO 982092 A		29-06-1998
		NZ 321626 A		28-10-1998
		PL 326671 A1		12-10-1998
		RU 2167160 C2		20-05-2001
		SI 863897 T1		31-10-1999
		SK 59998 A3		04-11-1998
		TR 9800827 T2		22-02-1999
		US 5929089 A		27-07-1999
		ZA 9609418 A		02-06-1997
WO 9514007	A 26-05-1995	AU 693142 B2		25-06-1998
		AU 1171295 A		06-06-1995
		CA 2176557 A1		26-05-1995
		EP 0729459 A1		04-09-1996
		HU 74386 A2		30-12-1996
		JP 9505298 T		27-05-1997
		NZ 276883 A		26-08-1998
		WO 9514007 A1		26-05-1995
		US 5578616 A		26-11-1996
WO 9320061	A 14-10-1993	AU 3944593 A		08-11-1993
		BR 9306190 A		23-06-1998
		EP 0633882 A1		18-01-1995
		FI 944605 A		30-11-1994
		HU 71353 A2		28-11-1995
		JP 7509219 T		12-10-1995

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/24654

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9320061	A	NO 943687 A	21-11-1994
		SK 118794 A3	07-06-1995
		WO 9320061 A1	14-10-1993
		US 5486526 A	23-01-1996
		US 5633382 A	27-05-1997
		US 5639775 A	17-06-1997